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CARCINOMA WITH CLINICOPATHOLOGICAL FEATURES. 
ABSTRACT 
Introduction : Colorectal carcinoma is the most common neoplasm of the 
gastrointestinal tract. COX-2 (cyclooxygenase-2) expression  is  upregulated  in 
colorectal carcinoma. Therefore its assessment would identify patients  
amenable to adjuvant therapy. As no studies  have been done across the Indian 
population as compared to western , the present study was done. 
Aims and objectives: To study COX-2 expression in colorectal carcinoma and 
correlate it with clinicopathological features like age, sex, tumor location, size, 
degree of differentiation, depth of invasion, lymph node status and TNM stage. 
Methods: 65 consecutive cases of colorectal adenocarcinoma  between January 
2009 to December 2013 were retrived from records of Pathology Department at 
PSG IMS&R. Immunohistochemical staining for COX-2 was done and 
correlated  with age, sex, tumor location , size, degree of differentiation, depth 
of invasion, lymph node status and TNM stage. 
Results : COX-2 was expressed in 86.2% of  cases and negative in 13.8%. 90% 
of  left side colonic carcinoma and 77.3% of right colonic carcinoma expressed 
COX-2. Among the lymph nodes with metastasis, 22.25% were COX-2 
negative, 25% low positive and  47.7% were high positive . High positive 
COX2 cases constituted 33.3% of stage I, 58.8% of stage II, 80% of stage III 
and 100% of stage IV tumors. About 56.6% of well differentiated, 66.6% of 
moderately differentiated and 100% of poorly differentiated carcinomas   
showed  high COX-2 expression. The   COX-2  overexpression   was associated 
with advancing stage of tumor, more frequent lymph node and distant  
metastasis,  decreasing degree of differentiation. 
Conclusion : Determination of COX-2 expression in colorectal carcinoma  
gives prognostic information. COX-2 overexpression   implicates advancing 
stage of disease. These patients can be treated with selective COX-2 inhibitors 
like Celecoxib,  Rofecoxib, L-745,337 and SC 58125 as an adjuvant  to chemo 
and radiotherapy. 
Key Words: Colorectal carcinoma, COX2,  COX2 inhibitor,  Metastasis. 
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INTRODUCTION 
           Colorectal carcinoma is the fourth common cancer in the world and 
second most common cause of cancer related death1. Epidemiological studies 
have shown a lower incidence of colorectal adenomas and carcinomas in 
subjects who have taken NSAIDS (Non Steroidal Anti-Inflammatory Drugs)  
for a long time which suggest a pathogenic  role for cyclooxygenase (COX -2) 
in colonic tumorigenesis. COX-2, an inducible isoform of cyclooxygenase is 
usually absent or present in low levels in normal colonic epithelium and is 
upregulated  in colorectal carcinoma. Assessment of this molecular factor would 
therefore help in identifying the patients who are likely benefit from COX-2  
inhibitor adjuvant therapy which attenuates the metastatic potential  of  
colorectal carcinoma, thereby improving the prognosis. Literature search 
revealed no such study across the  Indian population. Therefore the present 
study aims to evaluate COX-2  expression  in colorectal carcinoma and to 
correlate it with clinicopathological features- age, sex, tumor location, size, 
depth of invasion, histological type, degree of differentiation, lymph node 
metastasis and stage  of the tumor. 
 
 
 
  
 
 
 
 
 
 
Aims and objectives 
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AIMS AND OBJECTIVES : 
Primary Aim: 
 To study the COX-2 expression in colorectal carcinoma. 
Secondary Aim :  
To correlate the COX-2 expression with clinicopathological features – age, sex, 
tumor location, size, histological type, degree of differentiation, depth of 
invasion, lymph node metastasis and TNM (AJCC) stage. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Review of Literature 
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REVIEW OF LITERATURE 
Incidence and disease burden 
          Colorectal carcinoma is the most common neoplasm of gastrointestinal 
tract. According to global cancer statistics 2002, Colorectal carcinoma is the 
fourth most common cancer worldwide and second most common cause of 
death1 .They are most prevalent in North America, Europe, Australia and New 
Zealand compared to Asia and Africa1. In India, the incidence  is 30- fold lower 
than the former group1 . This geographical variation is due to different dietary, 
environmental  factors. According to United States Surveillance  Epidemiology  
& End Results  (SEER)  program, colorectal carcinoma accounts for 12% of all 
cancers with incidence rate of about  33.7 and 12.8 per one lakh for colon and 
rectal carcinoma respectively2. Mortality rate was about 15% according to 
American cancer society statistics(2000-2004)2. The incidence rate has been 
declining in the recent years considerably in North America due to modification 
of dietary habits and early screening3. Males are more frequently affected than 
females1. Incidence increases with age, most of the patients being above 40 
years with a median age of  71 years according to SEER statistics. In patients 
younger than 50 years, family history is necessary in assessing the carcinoma 
risk, as 1% is associated with Familial Adenomatous Polyposis and 5% with 
Hereditary Non polyposis Colon Cancer (HNPCC) 1. Location of colorectal 
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cancer in various sites of colon differs between male and female, and also 
reflect environmental, genetic factors and age of presentation3 . 
Location of tumor Males Females 
 Right colon 30% 40% 
Left colon 30% 30% 
Rectum 40% 30% 
 
ETIOPATHOGENESIS :  
           The pathogenesis of colorectal  cancer depends on environmental, diet  
and genetic factors, the polyposis syndromes being the most important ones. 
Environmental factors :  
          Apart from diet, decreased physical activity, occupational exposure, 
alcohol, smoking, inflammatory bowel diseases  are other factors having a role 
in the pathogenesis of colorectal carcinoma. 
Dietary factors:  
       ......  High intake of fat and animal protein provides an excess source of 
calories resulting in weight gain. In addition, it also cause increase in the 
formation of  hydroxyl radicals which in turn results in oxidative injury of 
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colonic epithelium predisposing to neoplastic progression 4,5. It also increases 
bile acid and cholesterol synthesis, the toxic metabolites of which are 
carcinogenic 4.  
          Good intake of fruits, vegetables with high fibre content and 
micronutrients like carotenoids,  flavinoids,  ascorbate,  isothiocyanate and 
phytic acid  decrease the risk of developing colorectal cancer as these  increase 
the defecation frequency and decrease mucosal contact time of potential 
carcinogens.  
          The consumption of vitamin A,C,D,E, calcium, selenium reduces the risk 
by their antioxidant action which prevent formation and neutralise the 
carcinogens 6,7. In addition, calcium decreases the bile acids and fatty acids 
mediated injury of colonic epithelium by converting them into insoluble 
calcium soaps, thereby decreasing epithelial cell proliferation7. Selenium, a 
cofactor of glutathione peroxidase   reduces oxidative  damage of epithelium.   
          The low fibre diet decreases the stool bulk and alters the intestinal flora 
resulting in increased free radicals which remains in contact with colonic 
mucosa due to increased transit time, causing epithelial injury 4. 
           Alcohol consumption results in positive energy balance and abnormal 
DNA methylation8. Smoking, tobacco chewing, snuff and pipes on prolonged 
use is associated with microsatellite instability and act as a tumor initiator 9.     
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          Obesity, sedentary occupation, excess energy intake, decreased physical 
activity in association with high fat intake is a risk factor. Increased physical 
activity cause stimulation of hormonal release, increase in peristalsis and neural 
reflex mechanism resulting in decreased mucosal exposure to carcinogens 10. 
          Individuals with prolonged exposure to metal dusts, plastics, organic 
solvents, fibreglass, fumes and asbestos are at increased risk for developing 
rectal cancer 1. 
Intestinal factors :  
          Increased risk of cancer is seen in patients with diverticulosis, ulcerative 
colitis, Crohn’s disease and adenomatous polyps 1. Carcinomas occurring in 
association with Schistosoma Japonicum infestation are  multicentric and 
present at an early age 1. 
Hormonal factors :  
          Type 2 diabetes mellitus shows an increase in insulin resistance and 
glucose intolerance. Increased  insulin  levels in Type 2 DM promotes epithelial  
proliferation and inhibit apoptosis of colonic epithelial cells favouring 
tumorigenesis 11. The increase in glucose level provides greater energy source 
for colonocytes.  
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         Estrogen receptors are highly expressed in colonic tumors which implicate 
the protective role of estrogen. 
            Increased gastrin and growth hormone levels have been implicated in 
colorectal tumors.  In colonic cancers, serum gastrin levels may be increased , 
probably due to autocrine secretion from tumor. The gastrin has growth 
promoting action. In persons with acromegaly, an increased growth hormone 
status resulted  in increased cell proliferation and tumor formation.1 
Others :  
          Radiation therapy for cancers of female genital tract and prostate  
increases the risk of colorectal carcinoma.  
          Surgical procedures  like cholecystectomy,  ileal conduits, gastric surgery 
for peptic ulcer may contribute to carcinogenesis. Epithelial proliferation occurs  
due to activation of  fecal carcinogens by the diverted urine. Gastric surgery for 
peptic ulcer may alter the bile acid metabolism  increasing unconjugated and 
secondary bile acids  predisposing to carcinoma1. 
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Predisposing  host  factors :  
          Among the endogenous factors, inflammatory bowel disease, genetic 
polyposis syndromes are important 2. 
Inflammatory bowel disease 
         Inflammatory bowel disease is a long standing chronic inflammatory 
process which includes Ulcerative colitis and Crohn’s disease. Numerous 
studies demonstrate an association between these diseases  and colorectal 
carcinoma. The pathogenesis includes two hypothesis, one is a normal immune 
response to abnormal environmental stimuli while other is an abnormal  
immune response to normal stimuli 12.  
          IBD is more common around the third decade.  In  long standing  IBD, 
with increasing duration of  disease, the risk of developing  precursor lesions 
like dysplasia or invasive carcinoma was higher 13. Patients with extensive 
colon involvement upto or proximal to hepatic flexure are at greater risk for 
developing colorectal cancer 13. The incidence begins to increase after 8-10  
years of  onset of  the symptoms with  an  incidence rate of about 5-10% and 
12-20%  after about 20 and 30 years of disease respectively 14. But when IBD is 
limited to left colon the risk of developing cancer increases after 15-20 years.  
          Patients with isolated ulcerative proctitis do not have greater risk for 
developing  cancer , incontrast to patients with pancolitis 13. Therefore routine 
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surveillance for dysplasia is recommended for patients with crohn’s or  
ulcerative colitis.  A routine colonoscopy every 1 or 2 years for lifetime is 
recommended 13. 
Polyps : 
           Polyps of the colon are predominantly of epithelial origin, categorised as 
hyperplastic,   adenomatous  and inflammatory polyp. 
Hyperplastic polyp:      
          About 25-30% of large intestinal polyps are hyperplastic in nature,   
grossly presenting  as pale sessile nodule  < 5mm in size with smooth glistening 
surface1. Three subtypes have been identified namely the Microvesicular 
hyperplastic polyp (MVHP),  Mucin  poor  hyperplastic polyp ( MPHP) and the 
Goblet cell hyperplastic polyp (GCHP).   
          Hyperplastic polyps in  general  has low malignant potential.  However 
mutations have been identified in MVHP  and  GCHP. The microvesicular 
hyperplastic  polyp  is  associated with V600E BRAF mutation   and activation 
of  MAPK (MAP Kinase)  pathway15. The surface colonocytes, in the absence 
of apoptosis persist, resulting in serrated morphology. The goblet cell type 
hyperplastic polyps are associated with KRAS mutation 15.  Characteristic 
microscopic features include  marked luminal serration, mitosis and mild 
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nuclear  atypia  at  the crypt  base, surface   maturation  and thicker collagen 
table 2. 
 
Adenomatous polyps:     
           Adenomas are common  premalignant  lesions of colon. They are 
classified as conventional, serrated or flat types. Conventional adenomas are 
subtyped as tubular, villous or tubulovillous adenomas 2. Polyps  occuring  in 
the context of hereditary colon cancer syndromes was usually multiple and 
present at a younger age group 1. Among   various colonic polyposis syndromes, 
Familial adenomatous polyposis with its attenuated form, Gardner’s syndrome, 
Turcot’s syndrome,  MYH associated polyposis and Lynch syndrome are most 
common 2. 
   Familial  adenomatous  polyposis: 
          Familial  adenomatous  polyposis has an autosomal dominant inheritance 
with  APC (Adenomatous Polyposis Coli)  gene mutation  ( a tumor suppressor 
gene). In addition KRAS and p53 mutations are also encountered. It is 
characterised by presence of more than 100 tubular adenomatous polyps 
involving the entire colon  which by definition harbours low grade dysplasia 2. 
Cyclooxygenase 1 expression has been  seen  in stromal cells in FAP at an early 
stage followed by COX-2 expression resulting in PGE2 mediated growth of the 
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polyp 16. Thus in addition to COX-2, COX-1 also plays a role in the initial 
stages of development of polyp 16.  
         Gardner’s syndrome,  an autosomal dominant condition with APC gene 
mutation, develop in addition to adenomatous polyps, desmoid tumor and 
osteomas.  
          Turcot’s syndrome shows coexistence of  FAP or Hereditary 
nonpolyposis colon cancer with central nervous system tumors. APC gene 
mutation or germline defect in DNA mismatch repair genes have been     
reported 2.   
          Attenuated  FAP  also known as hereditary colon cancer syndrome with 
mutation similar to FAP. Morphologically the condition differs from 
conventional FAP, by the presence of less than 100 polyps and the risk of 
developing colorectal carcinoma at an older age group 2. 
         MYH associated polyposis is an autosomal recessive syndrome with 
mutation in Mut Y homologue (MYH) gene which encodes an enzyme 
responsible for preventing mutation after DNA damage due to oxidation. 
Morphologically more than  30 adenomatous  polyps are seen with a high risk 
for colorectal carcinoma. 
          Mutation of DNA mismatch repair genes ( hMLH2, hMSH6, hMSH2, 
hPMS2 ) resulting in microsatellite instability is seen in  Hereditary Non 
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Polyposis Colorectal Cancer Syndrome (HNPCC), also known as Lynch 
syndrome . The polyps are of  adenomatous type, usually less than 10 in number 
with high grade dysplasia and increased risk for malignant transformation. 
   Morphology of adenomas :         
         Grossly, the adenomas may be pedunculated, flat or sessile. Tubular 
adenomas are pedunculated, small with surface lobulation while villous 
adenomas lack a stalk, present as flat or lobulated, sessile, large shaggy mass 
and have a broad base. Tubulovillous  adenomas  show  overlapping features of  
tubular and villous architecture ranging between  20-79% 1.  
          Microscopically tubular adenomas  show increase number of crypts with 
dysplasia of surface epithelium, focal tubular dilation and mixed inflammatory 
cells in the lamina propria. The villous adenoma consist of more than 80% 
finger like fronds with a core formed by lamina propria, lined by dysplastic 
epithelium. All  type of adenomas are composed of mixture of absorptive cells, 
intermediate cells, goblet cells, paneth cells and endocrine cells. Flat adenoma 
and villous adnenomas are most commonly associated with high grade 
dysplasia. Hypersecretory and clear cells are other rare types of adenomas 1.   
          Serrated adenomas are less frequently reported type of polyps. They may 
be single or multiple. Histologically serrated glands are  lined by less mature 
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stratified dysplastic cells with surface mitosis, papillary tufting and eosinophilic 
cytoplasm with increased nucleo-cytoplasmic ratio and prominent nucleoli.  
         Hyperplastic and serrated polyps constitute 7% of premalignant lesions in 
IBD 13. 
 Dysplasia  associated lesions : 
  Dysplasia  can be  associated with both inflammatory bowel disease and 
polyps. In 1981, Blackstone et al, described the term DALM or Dysplasia 
Associated Lesion or Mass in ulcerative colitis. The DALMs can 
morphologically resembles sporadic adenoma which was termed as adenoma 
like dysplasia  associated lesions or masses.  
          The differentiating features between DALMs and sporadic adenoma is 
that  the former shows bottom up growth pattern with dysplastic cells at the 
bottom of the crypts in the background of chronic active inflammation, while 
the latter shows top-down growth pattern with luminal surface of crypts lined by 
dysplastic cells 13. 
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PATHWAYS OF COLORECTAL CARCINOGENESIS : 
The molecular changes in colorectal adenocarcinoma are heterogenous 
including genetic alteration and epigenetic abnormalities 4. The two distinct 
forms of genomic instabilities are chromosomal instability and microsatellite 
instability. Till date at least three distinct pathways of colorectal carcinogenesis 
have been identified 2. 
1.APC / β catenin pathway 
2. Microsatellite Instability Pathway 
3.Serrated neoplasia pathway OR CpG Methylation pathway 
 
1.  APC / β catenin pathway : 
          APC gene mutation was identified commonly in individuals with familial 
adenomatous polyposis (17,18). Vogelstein et al described it as a type of 
chromosomal instability with multistep progression from hyperproliferative 
epithelium to adenoma of increasing size and dysplasia, finally resulting in 
invasive carcinoma 19. The members of this pathway are APC, KRAS, p53,      
β-catenin, DCC and DPC4 genes 4. 
          APC  gene is located in chromosome 5 , undergoes germline mutation in 
FAP patients and somatic mutation in sporadic adenocarcinomas 20. The APC 
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gene is a most important component of Wingless (WnT) signalling pathway. It  
act as “ Gate keeper gene” with negative regulation of colonic epithelial 
proliferation in colorectal neoplasia 2. Most colorectal cancer and adenoma 
patients have at least one allele mutation according to knudson hypothesis 4. In 
tumorigenesis, the second allele also mutated results in loss of  tumor 
suppressor effects 20. 
           β-Catenin can be dysregulated by APC gene mutation or CTNNB1 
mutation   (β catenin gene) 17. Normally APC gene causes ubiquitin mediated 
degradation of  β catenin  in cytoplasm, thereby preventing it from entering the 
nucleus where it induces cell proliferation by  interacting with transcription  of 
Myc and cyclin D 21.  
          KRAS are protooncogenes having role in signal transduction from growth 
factor receptors. Mutation cause autonomous cell proliferation. KRAS 
mutations follow loss of APC in the adenoma-carcinoma pathway 19. 
           p53 gene, located on chromosome 17 is a tumor suppressor gene. The 
most common functions are control of cell proliferation, DNA repair and 
programmed cell death. Arrest of cell cycle at G1 phase, inhibition of cyclin 
CDC2 or cyclin CDK complexes are also the functions of p53. Loss of wild 
type p53 due to mutation or deletion therefore is a major step in carcinogenesis 
because of  loss of check point in cell cycle and absence of DNA repair. This 
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results in amplification of unrepaired DNA and upregulated cell growth. p53 
overexpression is an important predictor of survival status in patients with 
lymph node positive colorectal carcinoma 1. 
          Loss of heterogenesity of DCC (Deleted in Colon Cancer) and 
SMAD4  or  DPC4 (Deleted in Pancreatic Cancer, locus 4) on chromosome 18 
is commonly seen in colorectal carcinoma. These genes encode TGF-β 
signalling proteins which normally inhibits cell cycle 4 and the mutation of 
TGF-β causes increased cell proliferation. Loss of SMAD4 gene  is seen  in late 
stages, suggesting it as a late event in carcinogenesis 4. 
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Sequence of events of APC /β  catenin pathway  4 
Normal colon with germline or somatic mutation of single allele of APC at 
chromosome 5. 
 
Hypermethylation and inactivation of second allele of the APC gene results in 
increased  β-catenin levels. The mucosa is put to increased risk for tumor 
formation. 
 
Subsequent KRAS and p53 mutations results in increased cell proliferation and 
inhibition of apoptosis 
 
ADENOMAS develop. COX-2 overexpression occurs (discussed in detail later 
in the review of literature) 
 
Together with loss of   heterogenesity of  SMAD4 &2 and increased telomerase 
activity, progression from adenoma to carcinoma occurs. 
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2. Microsatellite instability pathway: 
          Mismatch repair genes correct the genetic alteration occurring during 
DNA synthesis. In conditions with DNA mismatch repair deficiency, mutation 
accumulate in microsatellite repeats which is referred to as 
MICROSATELLITE INSTABILITY (MSI). Many of the microsatellites are 
located in noncoding regions.  
          When the microsatellites  located in promoter or coding region of the 
genes like TGF-β type II receptors, BAX proteins become unstable, 
uncontrolled cell growth and proliferation occur 4. These promoter regions are 
responsible for regulation of cell growth by encoding the TGF-β type II 
receptor  and  BAX proapoptotic protein. Normally TGF-β inhibit proliferation, 
so in the presence of TGF-β mutation, uncontrolled cell growth occurs with 
increased survival due to BAX loss. Other mutations in BRAF and CpG 
hypermethylation also develop in this defect 4. 
           MSI was initially discovered in HNPCC, most common cause of right 
sided colonic tumor with a higher tendency to be of mucinous, poorly 
differentiated type. There are three categories of microsatellite alteration  
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(a) MSS( Micro Satellite Stable), 
 (b) low level  MSI   
(c) high level MSI. 
           MSI-low level occurs with <30% unstable microsatellite loci and MSI-
high level show >30% microsatellite   instability loci 22. 
Sequence of the pathway 22 
In normal colon with germline or somatic mutations of mismatch repair genes 
          
 Alteration in second allele by Loss of Heterogenesity by methylation or 
               mutation of MLH1, MSH2,MSH6, PMS1 and PMS2. 
                   
                 Microsatellite instability is initiated 
 
Accumulation of gene mutations results in uncontrolled cell proliferation and        
inhibition of apoptosis by alteration in TGF-β RII, BAX, BRAF and others. 
                             
                       COLORECTAL CARCINOMA 
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3. SERRATED NEOPLASIA PATHWAY OR THE CPG 
METHYLATION PATHWAY 
          Jass et al, proposed that carcinomas arising by the serrated pathway  are 
heterogenous groups, the molecular profiles of which have been subtyped as 
follows 15,23. 
1.BRAF mutant, CIMP-H with MSI-high level. 
2.BRAF mutant, CIMP-H with MSS. 
3.Kras mutant, CIMP-L, MSS. 
[CIMP-H or L : CpG Island Methylation Phenotype-High level or Low level, 
MSI: MicroSatellite Instability, MSS: MicroSatellite Stable]. 
1.BRAF mutant / CIMP-H / MSI-H :  
          The colorectal carcinomas with this genetic profile are more 
common (9-12%) in elderly women, situated in right  colon, and are at 
high tumor stage without lymphnode or distant metastasis at presentation. 
The sessile serrated adenomas, a precursor lesion undergoes progressive 
methylation  and silencing of MLH1 (key promoter region)  resulting in 
high grade dysplasia and microsatellite instability. 
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 Prognosis is favourable. However  these tumors are resisitant to most 
non-surgical treatments like chemotherapy including 5-flurouracil, 
monoclonal EFGR inhibitors (cetuximab & panitumumab) 15. 
2.BRAF mutant / CIMP-H / MSS:    
           Sessile serrated adenomas with dysplasia in the absence of loss of MLH1 
gene are proposed precursor lesion of this subgroup of mutation (5-10%). 
Compared to conventional colorectal carcinomas, these tumours are often 
poorly differentiated and have higher incidences of tumor budding, 
lymphovascular and perineural invasion with lymphnode metastasis.  
          The genetic abnormalities includes methylation of different promoter 
region and silencing of p16, Tp53 and WnT pathway genes. These tumors have 
a poor prognosis. 
3. KRAS mutant / CIMP-L / MSS :   
         KRAS mutation with microsatellite stable subgroup is the largest group 
(15-20%) among other mutants. Serrated tubulovillous adenoma are the 
precursor lesions progressing via this pathway. Low level CIMP segregate these 
tumors as a subtype with poor prognosis 15. 
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Serrated morphology carcinoma : 
          Serrated carcinoma refers to the tumors with distinctive serrated 
morphology and derived via serrated neoplastic pathway. These carcinomas 
initially described by Jass and Makinon et al have defined the histological 
criteria. The World Health Organisation has recognised serrated carcinomas as a 
distinct subtype of colorectal carcinoma 15. 
          These serrated carcinomas are frequently seen in women and the common 
sites are caecum,  ascending colon followed by rectum 24. 
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SEQUENCE OF THE SERRATED PATHWAY 15 
                                          NORMAL MUCOSA 
BRAF / CIMP-H                                                     KRAS 
Sessile serrated adenoma                                 Traditional serrated adenoma  
                                                                         
Loss of MLH1           Loss of p16/ MGMT                    
SSA with dysplasia        SSA with dysplasia 
Subsequent MSI results                              Silencing of WnT pathway genes  
frameshift mutation of                                                                                               
TGFβ  receptor II                                                   TSA with high grade dysplasia 
BRAF/CIMP-H/MSI     BRAF/CIMP-H/MSS         KRAS/CIMP-L/MSS 
Colorectal carcinoma        colorectal carcinoma               colorectal carcinoma 
 
Comparing these three molecular profiles, the BRAF/ CIMP-H/ MSI has good 
prognosis but resistance to chemotherapy, while the remaining two mutations 
has poor prognosis but are sensitive to chemotherapy 15. 
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INFLAMMATORY BOWEL DISEASE ASSOCIATED 
CARCINOGENESIS : 
          Inflammatory Bowel Disease (IBD) associated carcinogenesis is a 
multistep process, starting from inflamed regenerative epithelium to hyperplasia 
to flat dysplasia and ends with invasive adenocarcinoma. The interaction of 
inflammatory cells like neutrophils and macrophages with colonic epithelium 
plays a key role in IBD-induced carcinogenesis. Various factors like reactive 
oxygen/nitrogen overproduction, cytokines, growth factors and  arachidonic 
acid metabolites, activated inflammation associated signal pathways, together 
with immune dysfunction contributes to carcinogenesis in IBD.  
          Similar to sporadic colorectal cancer the characteristic  molecular 
abnormalities are mutation in oncogenes, tumor suppressor genes and DNA 
repair genes with  genomic instability13. Chronic inflammation results in 
oxidative stress which plays a characteristic important role in this 
carcinogenesis. The oxygen and nitrogen free radicals  bind to target protein, 
DNA, RNA and result  in genetic  alterations,  aberrant methylation and 
genomic  insatability.   
          Free radicals cause chromosomal instability secondary to DNA 
translocation/ amplification/ deletion/ breakage/ telomere damage and p53 
mutations 25. In ulcerative colitis, telomere shortening has been linked with 
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dysplasia25. Interaction of free radicals with the cell membranes leads to lipid 
peroxidation results in mutation of p53 tumor suppressor gene. Aberrant 
activation of arachidonic acid pathways and COX-2 overexpression are 
important in IBD associated carcinogenesis 26. In ulcerative colitis, COX-2 
expression elevated along with mRNA expression in inflamed mucosa, 
dysplasia and in carcinomas.  COX-2 activates procarcinogens , increases free 
radical production and angiogenesis 26. 
          IBD associated carcinogenesis and sporadic carcinogenesis shows similar 
molecular changes. The difference in the timing and frequency of the alterations 
distinguish  both types.  p53 is a key factor in IBD associated carcinogenesis 
and KRAS mutation, loss of APC genes are less common and occur  late in 
carcinogenesis. Genes with methylation of CpG islands result in dysplasia 
throughout the mucosa with ulcerative colitis.  
           Aneuploidy is usually seen in patients with more than 10 years disease 
duration and is associated with dysplasia 15. Fluroscent In-Situ Hybridisation 
(FISH) analysis shows ulcerative colitis associated dysplasia or carcinoma 
exhibiting monosomies and polysomies.  
          Microsatellite instability was frequently associated with ulcerative colitis 
patient with dysplasia and carcinoma.  p53 mutation in adjacent mucosa, APC 
and KRAS mutation are less frequently associated with carcinogenesis in the 
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later stages of ulcerative colitis indicating that KRAS play a role at the later 
stages of carcinogenesis.  
          CpG island methylation with hypermethylation of cyclin dependent 
kinase inhibitors 2A (CDKN2A) or p16 and p14 are common in ulcerative 
colitis associated adenocarcinoma. The p14 hypermethylation was detected in 
50% cases . 
          In sporadic cancers the precursors are tubular adenoma.  In contrast, the 
dysplasia  in IBD are polypoid or flat and localised or diffuse. The concept of 
“Field Cancerisation” describes that the entire epithelium of upper  
aerodigestive tract has increased risk for premalignant lesions in IBD due to 
multiple genetic abnormalities 27. This concept was widely accepted for other 
organs including colon, importantly in IBD associated dysplasia. This clonally 
derived mutant cells with indistinguishable histological features are seen in 
inflamed segment of IBD. For example  the mutant TP53 or KRAS is detected 
across nondysplastic crypts as well as entire neoplasm 27. 
           Low grade dysplasia is associated with very short  telomerases,  high 
level of senescences together with DEC1( Deleted in Esophageal Cancer 1) 
overexpression. Above pattern is  reversed in high grade dysplasia, an important 
features in IBD associated carcinogenesis 13. 
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          The level of expression of an enzyme named α-methylacyl coenzyme A 
racemase (AMACR) ranging from negative in normal epithelium to high in 
invasive carcinoma. Hence  p53 and AMACR coexpression  are demonstrated 
in IBD associated carcinogenesis 15.  
 
CLINICAL FEATURES  : 
           Colorectal carcinomas shows wide range of clinical features from altered 
bowel habits, pain and tenesmus to surgical emergency like intestinal 
obstruction 17,18. The clinical symptoms differ depending on the location and 
stage of the tumor 1. Generally all patients have loss of weight, loss of  appetite 
malaise, weakness and fatigue.  
          Right side colon cancers are often polypoidal and patients remain silent 
because of  the soft stool consistency in this region or have features secondary 
to iron deficiency anemia, cardiac failure or angina pectoris. When  the tumor 
obstructs the lumen of appendix,  patients may manifest with symptoms similar 
to appendicitis. Most of the caecal tumours are however silent, present as an 
abdominal mass with metastasis 1. 
          Left sided colon cancers frequently presents with altered bowel habits like 
diarrhoea, alternating with constipation and incomplete rectal emptying 
sensation. In advanced stage, napkin ring like constriction can cause, 
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constipation and symptoms of obstruction .  In case of obstruction, the proximal 
colon undergoes ischemic change and rupture 1.  
        Bleeding is a frequent finding in rectal carcinoma 1. In advanced stages 
irrespective of the location , the tumours present with significant abdominal 
pain, perforative  peritonitis and colo-colic fistula 1. 
 
MORPHOLOGY: 
           Gross appearance of colorectal carcinoma depends on the stage of 
disease 2.  
          Small carcinomas present as red, granular, elevated circumscribed lesions 
resembling adenoma 1. Aberrant crypt foci (ACF) is the earliest morphological 
change in the epithelial neoplasms of the colon 1. 
           Large carcinomas are categorised into four types: 
(a) Polypoidal type growth pattern: 
           It is most commonly seen in caecum and ascending colon 
presenting  as a  bulky mass 2. Also referred to as fungating or exophytic 
pattern they are  characterised   by intraluminal growth with papillary 
surface and areas of ulceration. When seen in the caecum, they are 
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usually asymptomatic until the symptoms of anemia occurs due to 
chronic blood loss 1.  
(b) Ulcerated  or excavated type: 
             It is an infiltrating type with elevated edges and intramural 
growth18.  
(c) Annular or constricting type: 
          It is the circumferential involvement of colon resulting in napkin 
ring constriction as seen by double contrast study 2. The colon proximal 
to the constriction shows attenuation of mucosal folds and dilatation 2. 
Both the ulcerated and annular types are commonly seen in descending 
and transverse colon 18. 
(d) Diffuse infiltrative or linitis plastica: 
          There is diffuse flattening and thickening of mucosa with more of 
intramural spread in this growth pattern2. All types are relatively 
homogenous with areas of necrosis and infiltration upto the serosa 
resulting  in retraction of serosal surface 2. Tumors with high mucin 
contents  appear  gelatinous and glistening with separation of bowel 
layers 17. 
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MICROSCOPIC APPEARANCE: 
          Adenocarcinoma  is the most common type of colorectal cancer. The 
tumor cells in colorectal  carcinomas  are arranged in glandular pattern and less 
commonly as single infiltrating cells in the poorly differentiated tumors. The 
surface  of  the  tumors  show  papillary or villous pattern of arrangement 17.  
          The tumor cells are  pleomorphic, columnar cells with increased nucleo 
cytoplasmic ratio, eosinophilic cytoplasm and conspicuous nucleoli. Admixture 
of goblet cells, neuroendocrine  cells and paneth cells are also encountered. The 
tumor confined to mucosa is grouped as intramucosal and further invasion 
towards the  serosa  increased the tumor staging.  
          Inflammation and desmoplastic reaction are often seen in the surrounding 
stroma.  Hyperplastic changes like taller and tortuous glands are most 
commonly seen at the edges of the tumor.   Lymphovascular and perineural 
invasion has prognostic significance 17. 
          Adenocarcinomas are graded on the basis of extent of glandular 
differentiation into (1) Well, Moderately and  Poorly differentiated   or (2) Low 
grade [well and moderately differentiated] and High grade [ poorly and 
undifferentiated]. More than 95%, 50-95% and 5-50% of glandular 
differentiation are seen in well, moderately and poorly differentiated carcinomas 
respectively18. Tumors with less than 5% glandular differentiation are 
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categorised as undifferentiated type 18. These tumors have DNA mismatch 
repair deficiency and poor  prognosis 2. 
Other types of carcinomas: 
Mucinous carcinoma: 
            Mucinous  carcinoma are most frequently seen in young patients with 
Hereditary Non Polyposis Colon Cancer syndrome2. The Conventional 
adenocarcinomas can have significant mucinous component. WHO 
recommends the term  mucinous carcinoma  when  > 50% of  tumor cells 
produce  mucin 18.  
          The tumor epithelium are in acinar, clumps or  single cell arrangement 
and these cells are freely floating in pools of mucin 18. Microsatellite instability 
and previous villous adenomas are the most common associated features 1. 
Mucinous carcinomas have very poor prognosis due to advanced stage at 
presentation,  extensive lymphnode and pericolonic  involvement  17.  
          There are two subtypes, colloid and signet ring cell carcinoma. 
           In colloid carcinoma, malignant disrupted glands are seen floating in 
pools of mucin.  Association with HNPCC is frequently seen 1. 
          Signet  ring cell carcinoma is a rare tumor seen in young patients with 
high microsatellite instability 17. Microscopically, the criteria for diagnosis is 
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the  presence of >50% of cells with prominent  intracytoplasmic  mucin 18. 
These cells can be  distributed in mucin pools or diffusely infiltrating the bowel 
wall 18. The prognosis is poor due to advanced stage and frequent metastasis 17. 
 
Linitis plastica or Diffuse carcinoma:  
          Non signet ring cell carcinomas may present with diffuse growth pattern 
of neoplastic cells 2. Marked  desmoplasia results in thick rigid colon grossly 1. 
Left colon is the most common site for this subtype with poor prognosis 1. 
 
Undifferentiated carcinoma:  
          The rare undifferentiated type are grossly seen as  bulky soft mass with 
extensive necrosis2. According to WHO, the carcinomas with no gland 
formation or less than 5% gland formation are described as undifferentiated 
carcinoma 18. 
           Histologically, the neoplastic cells are seen in sheets, cords and 
trabecular pattern with extensive necrosis and absence of desmoplasia . These 
tumors have DNA mismatch repair deficiency and poor prognosis 2. 
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Medullary carcinoma :  
          Medullary variant is more frequently seen in the right colon  with 
associated Microsatellite Instability17. Microscopically, the malignant cells are 
arranged in sheets with abundant eosinophilic cytoplasm, vesicular nuclei, 
prominent nucleoli and characteristic lymphocytic infilteration 18. Prognosis is 
favourable compared to poorly or undifferentiated carcinoma 18. 
 
Small cell carcinoma :  
          Adenocarcinomas can exhibit neuroendocrine differentiation ranging 
from scattered endocrine cells, mixed composition to predominantly small cell 
(neuroendocrine) carcinomatous pattern. Microscopically  it is characterised by 
presence of sheets of small cells with  hyperchromatic  nuclei. Foci of glandular 
differentiation can be present. Prognosis is poor with early lymphnode  and 
distant metastasis 17. 
 
Adenosquamous carcinoma :  
          This is an unusual type of carcinoma, presents in young patients in 
advanced stage 1. These tumors are usually associated with paraneoplastic 
secretion of parathyroid hormone and hypercalcemia 2. Microscopically, both 
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squamous carcinomatous and adenocarcinoma components are present in 
separate areas or admixed 18. Prognosis is poor compared to conventional 
adenocarcinoma 1. 
 
Squamous cell carcinoma : 
               Pure SCC is very rare in large bowel, caecum being a common 
location 18. Criteria to diagnose primary squamous cell carcinoma of large 
bowel are: 
 (a) No evidence of squamous cell carcinoma in any other primary sites which 
could provide a metastatic source or direct extension. 
 (b) No continuity with the anal squamous epithelium. 
(c) No evidence of associated squamous lined fistula in the affected bowel 
segment  
(d) No glandular differentiation.  
             The prognosis is worse than adenocarcinoma 2. 
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Spindle cell or Sarcomatoid carcinoma:  
          Extremely  rare tumor of elderly persons.  Grossly present as bulky tumor 
with abundant hemorrhage. Microscopically, biphasic growth pattern  is seen 
composed of epithelial and mesenchymal components. The mesenchymal 
component may be smooth muscle, osseous or cartilaginous type. The tumor 
has TP53 mutation in both epithelial and mesenchymal component. Highly 
aggressive tumor  with poor prognosis 2. 
Serrated adenocarcinoma :  
          Serrated adenocarcinoma, a recently recognised entity arises from 
serrated or hyperplastic polyps. Pathogenesis reveals high degree of methylation 
and low or high level microsatellite instability 28. 
           Microscopically, tumor cells are  arranged in serrated, trabecular or 
mucinous growth pattern with abundant eosinophilic cytoplasm, preserved 
nuclear polarity,  condensed chromatin without any necrosis. The characteristic 
microscopic appearance has been described earlier. 
Rare variants: 
          Apart from above mentioned types, giant or pleomorphic cell, clear cell, 
basaloid, hepatoid, paneth cell rich (crypt cell carcinoma), oncocytic and 
carcinosarcoma are also reported 18. 
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STAGING OF COLORECTAL CARCINOMA 17 
          The different staging systems for colorectal carcinoma include Duke’s, 
Astler and Coller and American Joint Cancer Committee (TNM) staging. The 
aim of all staging systems is to predict the prognosis and to guide treatment. 
 
DUKE’S STAGING : 
 In 1932, Duke established a staging system 
A – Tumor confined to mucosa and submucosa 
B - Tumor extend into bowel wall 
C - Tumor extend beyond bowel wall with lymph node metastasis 
 
ASTLER COLLER STAGING :  
          It is a modification of   Duke’s staging  with the addition of   stage D to 
include tumors with distant metastasis : 
A-Tumor confined to mucosa and submucosa 
B-Tumor invades into muscularis propria with no lymph nodes 
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B1-Tumor invade into muscularis propria 
B2-Tumor invade through muscularis propria into serosa 
C-Tumor invades into muscularis propria with lymph node deposits 
C1- Tumor invade into muscularis propria with lymph node metastasis 
C2-Tumor invade through muscularis propria into serosa with lymph node 
metastasis 
D-Tumor with distant metastasis 
 
AMERICAN JOINT CANCER COMMITTEE  (TNM) Staging: 
Primary tumor (T ) 
Tx – Primary tumor cannot be assessed 
T0 – No evidence of primary tumor 
Tis – Carcinoma in situ ( Intraepithelial or invasion of lamina propria) 
T1- Tumor invades submucosa 
T2 – Tumor invades into muscularis propria 
T3 – Tumor invades through the muscularis propria into subserosa or into 
nonperitonealised   perirectal or pericolic tissues 
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T4 – Tumor directly invades other organs or structures or perforates the visceral 
peritoneum or tumor adherent to other organs. 
N :Regional lymph nodes: 
Nx – Regional lymph nodes cannot be assessed 
N0 – No regional lymph node metastasis 
N1 – Metastasis in 1 to 3 regional lymph nodes 
N2 – Metastasis in 4 or more regional lymph nodes. 
 
Distant metastasis: 
Mx – Presence of metastasis cannot be assessed 
M0 – No distant metastasis 
M1 – Distant metastasis 
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STAGE GROUPING 
STAGE T N M 
STAGE 0 Tis N0 M0 
STAGE I T1 
T2 
N0 
N0 
M0 
M0 
STAGE II A T3 N0 M0 
STAGE IIB T4 N0 M0 
STAGE III A T1-T2 N1 M0 
STAGE III B T3-T4 N1 M0 
STAGE III C Any T N2 M0 
STAGE IV Any T Any N M1 
 
 
          The TNM staging recommended by AJCC (American Joint Committee) 
has replaced the Dukes and Astlers Collers staging system. The limitations of 
different staging systems compared to the AJCC (TNM) staging can be assessed 
from the comparison table below: 
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STAGING T N M Duke’s 
staging 
Astler 
coller’s 
Staging 
0 Tis N0 M0 - - 
I T1 
 
T2 
N0 
 
N0 
M0 
 
M0 
A 
 
A 
A 
 
B1 
IIA T3 N0 M0 B B2 
IIB T4 N0 M0 B B3 
III A T1-T2 N1 M0 C C1 
III B T3-T4 N1 M0 C C2/C3 
III C Any T N2 M0 C C1/C2/C3 
IV Any T Any N M1 - D 
 
 
           In Astler collar, tumor involving mucosa alone is graded as A, but in 
Duke’s  staging system , stage A  are tumors involving mucosa and submucosa 
and in TNM, stage I are the tumors with mucosa, submucosa and / or muscularis 
propria involvement.  Other stages are more or less equally categorised. 
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           In TNM staging, the nodal involvement is subgrouped according to the 
number of  lymph nodes  with metastasis, while in the other staging systems 
only the presence or absence of lymphnode involvement is taken into 
consideration. 
 
 PROGNOSTIC FACTORS IN COLORECTAL CARCINOMA: 17 
1.Age and sex:   
          Tumors  seen in  very young and very old patients have poor prognosis. 
In very young patients, delay in diagnosis results in advanced stages. 
Association  with ulcerative colitis is often present and are histologically of 
signet ring and mucinous carcinoma type. Females have good prognosis than 
males. 
 
2. Tumor location:  
          Studies reveals that lesion in left colon have better prognosis than right 
colon and rectum while the contrary has been observed in other studies. 
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3. Tumor multiplicity:  
           Both synchronous and  metachronous malignancies have similar survival 
rate like solitary adenocarcinoma. 
 
4. Local extent of tumor:  
           Polyp with focal microscopic carcinoma confined to mucosa and 
submucosa has excellent prognosis. Tumors with extension beyond the wall 
with regional lymph node metastasis have poor prognosis. 
 
5.Tumor size:  
          A minor relationship was noted between tumor size and  lymph node 
metastasis, prognosis. 
 
6. Tumor edge: 
           Adenocarcinoma with nonpolypoidal edge have worse prognosis than 
polypoidal carcinoma. 
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7. Obstruction and perforation:   
          Both occur when there is extensive infiltration of  bowel wall and it 
indicates worse prognosis. 
 
8. Tumor budding: 
           Tumor cells singly or  >5% cells clusters at the invasive tumor front is a 
strong prognostic indicator for poor outcome. 
 
9. Microscopic type: 
            Among the various types of  adenocarcinoma,  mucinous, signet ring 
and anaplastic carcinoma have worse prognosis while medullary carcinoma has 
better prognosis. 
 
10. Tumor margin and inflammatory reaction: 
           Tumor with pushing type margins and marked lymphoplasmacytic 
infilterate at the interphase between tumor and adjacent bowel tissue have a 
better prognosis.  Presence of eosinophils  and  dendritic cells in the stroma also 
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associated with good prognosis. But the presence of mast cells indicate a 
comparatively poor prognosis. 
 
11. Lymph node involvement:  
            The extent of   lymphnode  metastasis determines the survival rate of the 
patients. Greater, the number of lymph nodes involved, the worser is the 
prognosis.  Micrometastasis of lymph node detected by IHC(CK 20) or PCR 
(for CEA) have prognostic significance. 
 
12. Tumor angiogenesis :   
          Tumors with significant angiogenesis have high  chance of recurrence, 
hence decreased survival rate. 
 
13. Tumor thickness:  
          Increased thickness of tumor in central depressed region correlates with 
lymphnode and distant metastasis and an unfavourable prognosis. 
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14. Angiolymphatic invasion:   
          The tumor invading veins particularly extramural vessels, is associated 
with more frequent distant metastasis and decreased survival rate. Lymphatic  
vessel invasion has adverse prognosis if patients have stage III disease. 
 
15. Perineural  invasion:  Perineural invasion has unfavourable prognosis. 
16. Pericolonic tumor deposits:  They are associated with poor prognosis. 
 
17. Surgical margin:   
          Presence of tumor < 2mm from the radial margin is a bad prognostic 
indicator with increased local recurrence. 
 
18. Microscopic grading:  
           The less differentiated tumors have poor prognosis. The grading is 
determined by worst pattern rather than the predominant one. 
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19. Pattern of lymphnode reaction:  
          The regional lymphnodes  may show evidence of cell mediated immune 
response characterised by paracortical expansion with immunoblasts and sinus 
histiocytosis. These patients has better survival rate than others without any 
change. 
 
20. Staging of tumor:   
         The patients in advanced stage of the tumor have poor prognosis. 
 
21. Serum CEA levels:  
          Increased serum carcinoembryonic  antigen about  more than 5 ng/ml 
have an adverse prognosis. 
 
22. Mucin related antigens: 
           The colorectal carcinomas with mucin associated antigens like sialyl-Tn 
and sialyl-lewis expression have aggressive outcome. MUC1, is   an 
independent  prognostic factor  associated with high chance of progression of 
the tumor. 
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23. HLA-DR and BCl-2 expression: 
     Both HLA-DR and BCl-2 expression are associated with good prognosis. 
 
24. TGF-β Mutation:  
          TGF-β type II receptor mutation with high levels of Microsatellite 
Instability have favourable prognosis. 
 
25.Oncogenes and tumor suppressor gene expression: 
           Presence of  MSI is associated with better patient survival. On the other 
hand, KRAS mutation, overexpression p53 and lack of  p27 expression are 
associated with poor prognosis. 
 
26. Allele loss of chromosome 18q: 
           Loss of chr18q  allele results in unfavourable prognosis. But retention of 
the alleles in microsatellite stable tumors indicate favourable outcome with 
good response to adjuvant chemotherapy in stage III carcinoma. 
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27. DNA ploidy:  
           In rectal carcinoma, tumors with aneuploidy have increased risk of 
recurrence and unfavourable prognosis. 
 
28. pRb and p16:   
        Poorer outcome was seen in patients with aberrant expression of pRb and 
p16. 
 
29. Claudin 1:  
          Claudin is a tight junction associated protein. Loss of claudin results in 
poor prognosis with high chance of recurrence. 
 
30. Fascin:  
          Immunohistochemical detection of increased fascin expression indicates 
decreased survival rate.  
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WHAT IS  CYCLOOXYGENASE ? 
           Cyclooxygenase (COX) or prostaglandin H2 synthase (PGHS) is the 
enzyme that catalyses the first two steps in the biosynthesis of prostaglandins    
( PGs)  from the substrate arachidonic acid ( AA ). These include the oxidation 
of AA to PGG2 ( hydroperoxy endoperoxide) and reduction to PGH2 ( hydroxy 
endoperoxide) . 
          
           Two isoforms of this enzyme exist : COX-1 and COX-2 29. The PGH2 is 
then converted to PGE2, PGF2 , prostacyclin, PGD2 and thromboxane by 
specific enzymes as shown in the flow chart below (Fig 1) 30 . 
          
           Cyclooxygenase-1 (COX-1) was first obtained from bovine vesicular 
glands in 1976 31 and COX-2 was discovered by Daniel Simmons laboratory at 
Brigham university in 19911. The COX-2 gene (PTGS.2 gene, prostaglandin 
synthase-2) in humans has been identified on chromosome 1q25 32. 
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Fig 1 : shows the biosynthesis of prostaglandins
30
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Tissue distribution of cox-1 and cox-2: 
          COX-1 is the ‘constitutive isoform’ expressed in nearly all cell types 
under basal conditions. It has been found in blood vessels, interstitial cells, 
smooth muscle cells, platelets, mesothelial cells, stomach and kidney 33. 
          COX-2 isoform is not constitutive in most tissues except in placenta, 
macula densa of the kidney and brain 31. COX-2 is however inducible in many 
cell types- synoviocytes, endothelial cells, chondrocytes and macrophages by 
cytokines like IL- 1 (Interleukin-1), Interleukin-2, Tumor Necrosis Factor-alpha 
and bacterial lipopolysaccharide (LPS) 34. Cytokines such as interleukin-4, IL-
10, IL-13 and corticosteroids decrease the induction of COX-2. 
Functions of cox-1 and cox-2: 
Stomach:  
          Cytoprotective  prostaglandins eg: prostacyclins are synthesized by   
COX-1, although small quantities of COX-2 is expressed constitutively 35.  
COX-1 promotes crypt stem cell survival and proliferation. It maintains the 
integrity of the mucosal epithelium by enhancing mucosal blood flow by 
vasodilation. 
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Kidney:  
          PGs are synthesized mainly by COX-1, low levels of COX-2  has been 
detected. PGs do not maintain normal renal blood flow, but are important in a 
compromised kidney and in patients with congestive heart failure, cirrhosis and 
renal insufficiency 29. 
Platelet: 
           The only isoform detectable in the platelet is COX-1 which produces 
thromboxane. Thus prophylaxis against thromboembolic disease can be 
achieved by aspirin. 
Gestation and parturition: 
           Both COX-1 and COX-2 are expressed in the uterine epithelium and are 
important for implantation of the ovum and in angiogenesis during placenta 
formation. COX-2 plays a role in inducing uterine contractions during labor. In 
addition both COX-1 and COX-2, the former at a higher level, is expressed in 
fetal hearts, kidneys, lungs, brain and the decidual lining of uterus 36. 
CNS: 
           COX-1 is distributed in neurons throughout the brain, being most 
prevalent in forebrain. COX-2 expression is confined to cortex, hippocampus, 
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hypothalamus and spinal cord. In addition, COX-2 is also detected in the non-
neuronal cells.  
          The major PGs of the CNS are PGE2 and PGD2 which are involved in 
modulation of autonomic nervous system and sensory processing 37. PGE2 
generates signals that activate the thermoregulatory centre of the anterior 
hypothalamus thus playing a role in febrile response. The COX-2 induced in the 
endothelial cells of cerebral blood vessels is responsible for PGE2 release 38 . 
           In the spinal cord, the nociceptive process is brought about by COX-2 
causing hyperalgesia. 
Cox-2 in colon:   
               COX-2 expression in the normal colonic mucosa is either low or 
absent 39. Low levels of COX-2 are derived from macrophages, vascular 
endothelial cells and neuroendocrine cells in the normal mucosa 39. However it 
is an early response gene that is induced rapidly in response to growth factors, 
cytokines, oncogenes and phorbol esters 40.  
          The promoter region of COX-2 consist of many transcription factor 
binding sites such as nuclear factor Kb, nuclear factor of IL-6, AMP (Cyclic 
Adenosine Monophosphate) and hypoxia inducible factors (HIF-1) – all of 
which upregulate COX-2 41 . 
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STRUCTURE OF CYCLOOXYGENASE: 
          COX-1 and COX-2 have a similar molecular weight of  70K.Da and are 
almost identical in length. The tertiary and quarternary structures are also 
identical (Fig 2A). Each subunit has three structural domains: a short N-terminal 
epidermal growth factor (EGF) domain, an alpha-helical membrane binding 
moiety and a C-terminal catalytic domain 42.  
          COX-1 and COX-2 are bifunctional enzymes that carry out  two 
consecutive chemical reactions. Both  the  cyclooxygenase and the peroxidase 
active sites are located in the catalytic domain, which accounts for 80% of the 
protein.  
          Around 63% of their 600 aminoacids are in an identical sequence. Some  
substitutions are seen among the two namely- Isoleucine in COX-1 is 
exchanged for valine in COX-2 at positions 434 and 523 (Fig 2B). 
           
            Inspite of the structural identity, differences are seen in substrate and 
inhibitor selectivity. COX-2 acts on a wider range of fatty acids as substrate 
which include α-linolenic acid, linoleic acid than COX-1 29 . 
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Fig 2A  : Shows the overlapping structure of COX-1 and COX-2 
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Fig2B :  the structural variation between COX-1 and COX-2
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COX-2 AND INFLAMMATORY BOWEL DISEASE : 
          Crohn’s disease characterized by chronic inflammation may occur at any 
level of the digestive tract.  Mutations in the NOD2 / CARD 15 gene located on 
chromosome 16  is the predisposing event for the development and maintenance 
of the inflammatory process.   
          Overexpression of COX-2 has been seen in both the epithelial cells and 
inflammatory cells in response to the inflammatory cytokines 43. Romero and 
others have found a significant association between COX-2 expression and 
epithelial alterations such as ulceration, mucin depletion, presence of paneth 
cells 43. COX-2 overexpression was more frequently seen in the epithelial cells 
than in inflammatory cells. COX-2 immunostaining was demonstrated in 
normal mucosa in the control group of  Romero’s study in contrast to other 
studies which have reported the  absence of  the expression in normal 
epithelium 44. 
         As already reviewed, extensive ulcerative colitis of more than 8 years 
duration is an important risk factor for colonic epithelial dysplasia and 
adenocarcinoma13 .  Agoff and others have observed COX-2 expression in both 
the actively inflamed, non dysplastic mucosa and in non inflamed mucosa in all 
stages of neoplastic progression. COX-2 overexpression has been demonstrated 
in low -grade dysplasia, high-grade dysplasia and adenocarcinoma 45,46 . The 
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authors documented a more uniform diffuse cytoplasmic expression in all 
grades of dysplasia compared to adenocarcinoma where the COX-2 expression 
was not uniform with only 50% of cells staining in foci, although some foci had 
marked, uniform COX-2 overexpression 45 . 
 
ROLE OF COX-2 IN CARCINOGENESIS: 
          COX-2 induction has been associated with various premalignant and 
malignant lesions of colon, lung, breast, prostate, bladder, stomach and 
esophagus 41. COX2  and its major downstream product PGE2 play an important 
role at multiple levels in colorectal carcinogenesis 47. COX-2 is involved in 
activation and formation of carcinogens, inhibition of apoptosis, providing 
replicative potential, production of angiogenic factors and enhancing the 
metastatic potential40. 
 
Mechanism of overexpression of COX-2 in colorectal carcinoma : 
           Activating mutations in the PTGS2 gene, the gene encoding COX-2 in 
humans have not been reported but other mechanisms that cause COX-2 
overexpression include the activation of WnT pathway, loss of APC gene and 
RAS-MAPK pathway via the growth factor receptors- EGFR, C-Met 47 ( fig 3). 
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Mechanism of cox-2 carcinogenesis 47 : 
(i)Evasion of apoptosis 
(ii) Providing self sufficiency of growth signals 
(iii) Decreasing the sensitivity to antigrowth signals 
(iv) Providing limitless replicative potential 
(v) Sustaining angiogenesis 
(vi) Tumor progression- Invasion and metastasis 
(vii) Evasion of antitumor immune response. 
 
Fig3 :  Shows COX-2 activation pathways
 47
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(i)Evasion of apoptosis: 
          COX-2 increases the expression of  bcl-2, antiapoptotic protein 47 . In 
addition it also increases the cell survival by activating the survival pathways 
such as PI3K /AKT (Phosphatidyl Inositol triphosphate / AKT), cAMP / protein 
kinase A signalling and PPAR  (nuclear peroxisome proliferator – activator 
receptor – delta ) pathways 47. The inhibition of  Fas- mediated apoptosis is 
another mechanism observed in cholangiocarcinoma 48. Thus both the extrinsic 
and intrinsic pathways of apoptosis are inhibited.  
          The PPAR acts as a transcriptor factor, controlling the expression of 
genes involved in lipid metabolism. The dietary  fat provides agonist ligands for 
PPARs. Thus COX-2 overexpression  along with increased intake of dietry fat 
together play a role in carcinogenesis 49 .   
          The suppression of apoptosis by COX-2 also determines the susceptibility 
of tumor cells to radiotherapy and chemotherapy. COX-2 overexpression 
decreases the sensitivity of  tumor cells to cytotoxic therapy 47 . 
(ii) Providing self-sufficiency of growth signals :    
           As described above COX-2 / PGE2 activate PI3K / AKT, RAS-MAPK / 
ERK, EGFR signalling and cAMP / protein kinase A pathways by which tumor 
cells acquire growth autonomy even in the absence of activating mutations. 
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More important is the activation of the APC/β catenin pathway 47. Mechanisms 
prevail within the tumor to maintain the overexpression of COX-2.  
          During hypoxia, the HIF-1 (Hypoxia- Inducible Factor-1)   upregulates 
COX-2 expression which activates the RAS-MAPK pathway which acts in a 
positive feedback loop to maintain the COX-2 / PGE2 50. 
 
(iii) Insensitivity to antigrowth signals :    
          Overexpression of COX-2 down regulates the TGFβ  type II receptor 
(Transforming Growth Factor β)  which normally blocks the cell progression 
through G1 phase of cell cycle by suppression  of  c-MYC and activation of 
cycle cycle inhibitors. 
          Another mechanism is to block the differentiation of crypt epithelial cells 
in the upper third of the crypt, a physiological process occurring in the normal 
crypt epithelium. The progenitor proliferating cells in the lower third of the 
crypt become differentiated and are shed into the lumen. This is blocked by 
COX-2 / PGE2 by the activation of APC / β catenin pathway which maintain 
cells in a progenitor state. Few studies have shown that the COX-2 /PGE2 can 
directly block the differentiation 47. 
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(iv) Limitless replicative potential :  
           The proliferative compartments in the intestinal crypts are maintained 
through activation of the WnT pathway. Perturbations of the APC /β catenin 
pathway have been detected in aberrant crypt foci, the earliest lesions of 
colorectal tumor. 
           Following the loss of APC gene, there is increased expression of COX-2. 
This further activates the activity of the already elevated levels of the β catenin 
following the loss of APC. The β catenin translocates to the nucleus and acts as 
a transcription factor along with TCF-4 (T-Cell Factor 4) complex. The             
β catenin – TCF4 complex binds to specific target genes – c MYC, cyclin D, 
PPARs,  COX-2 and  increase  their levels thereby causing cell proliferation.  
On the other hand,   by increasing the COX-2 levels, a positive loop is formed 41 
(Fig 4,5). TCF binding sites have been identified in the promoter region of 
COX-2. 
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(v) Sustained angiogenesis :   
          COX-2 induces the production of angiogenic factors such as VEGF 
(Vascular Endothelial Growth Factor) and b-FGF (basic- Fibroblast Growth 
Factor). It also activates the integrinαVβ3   which is essential for endothelial 
survival,  spreading and migration 51. Wu and others in their study have found a 
strong correlation between COX-2 expression and VEGF expression both by 
immunohistochemistry and RT-PCR 52. 
 
Fig 4 : shows COX-2 overexpression  by free β catenin  following 
loss of APC . COX-2 in turn stimulates β catenin forming a 
positive loop 
41
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Fig 5 : shows  colorectal carcinogenesis and action of COX-2 inhibitors . 
Loss of APC gene is followed by induction of COX-2 causing the progression 
of carcinoma. Defects in DNA mismatch repair genes(MMR)  occur  further 
during carcinogenesis .The heavy arrows show points at which inhibition of 
COX-2 will block progression.
30
 
64 
 
 
(vi) Tissue invasion and metastasis : 
          As COX-2 / PGE2 levels increase, there is loss of E- cadherin and 
transactivation of  Hepatocyte growth factor / c-Met  signalling which 
contribute to tumor progression.   
          Loss of  E cadherin is associated with elevation of vimentin leading to 
epithelial-mesenchymal transition (EMT) which makes the tumor cells more 
migratory 53. HGF / c-Met increases β catenin and urokinase type plasminogen 
activator receptor expression which favours proliferation and invasion 
respectively47.  A strong expression   of  MMP-2 (Matrix Metalloproteinase-2) 
has been identified in cells with COX-2 expression thereby increasing the 
invasiveness of the COX-2 expressing neoplastic cells by 6 times 54. 
 
(vii) Evasion of antitumor immune response :   
           Cytotoxic CD8 T cells elicit antitumor response. PGE2 shift the 
production of cytokines away from a TH1 cell profile thereby reducing the 
activation of CD8 T cells 55 . 
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            In addition to these mechanisms, malondialdehyde, a by product of 
COX-2 mediated prostaglandin synthesis and lipid peroxidation is mutagenic 
and causes genetic damage 56. 
COX-2 AND ITS RELATIONSHIP WITH TUMOR BIOLOGICAL 
CHARACTERISTICS: 
Among the many prognostic factors reviewed earlier in this study, depth of 
invasion, stage of tumor, presence of  lymph node metastasis, distant metastasis, 
vascular and neural invasion are the important factors in determining the 
prognosis. The relationship of COX-2 expression with each of these has been 
discussed below: 
(i) Depth of invasion : 
           A significant association between COX-2 expression and the depth of 
invasion has been described by Soumaro LT and others in their study of 288 
resected specimens of colorectal carcinoma 57. COX-2 expression increased 
from 56.4% in T1 and T2 tumors to 74.1% and 96.3% in T3 and T4 tumors 
indicating the role of COX-2 in tumor progression.  
          A similar association has been seen by Wu AW and others in their study 
of colorectal carcinomas and adenomas. A strong COX-2 expression was seen 
in colorectal carcinoma, a moderate expression in adenoma and a weak to 
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absent expression in normal mucosa. Further a higher COX-2 positive T4 cases 
were seen compared to the T3 tumors 58 .  
          Comparing the COX-2 mRNA levels between the colorectal carcinoma 
and the normal mucosa by PCR method, it has been seen that COX-2 expression 
was significantly lower in the normal mucosa. In this study, Fugita and others 
further have demonstrated that COX-2 levels are significantly higher in tumors 
with deeper invasion 59 .  
          Other studies 60 however did not show an association since tumors were 
staged by Duke’s system.  The Dukes system does not definitely differentiate 
between different levels of invasion in the bowel wall 60. 
(ii) Stage of tumor : 
            Strong correlation between the stage of colorectal carcinoma and COX-2 
expression has been documented by many series of studies in the literature. 
Sheehan KM and others found that patients with high COX-2 expression  (grade 
4  ie. expression in  >50% tumor cells) were 4 times more likely to be classified 
as Dukes C and D than the patients with COX-2 expression in <20% of tumor 
cells 61. Only the percentage of positive cells were taken into account in this 
study. The intensity of staining was not considered in the grading.  
          Similarly in another study, comparing the COX-2 expression with 
microvessel density,  Masunaga R and others have observed a strong association 
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between COX-2 expression and Dukes stage B, C and D 62. Both the percentage 
of cells and the staining intensity were included in assessing the COX-2 
expression in this study.  
          A similar correlation was noted in two other studies by Al-Maghrabi 63 
and Soumaro 59 where the tumors were staged by AJCC system ( American 
Joint Committee Cancer staging system). In the former higher COX-2 
expression was seen in stage III / IV tumor compared to stage I /II, while in the 
later a gradual increase was observed from stage I to stage IV. 
(iii) Lymph node metastasis: 
          Patients with high COX-2 expression were 4 times more likely to have 
lymph node metastasis 61 . This finding by Sheehan K M and others has been 
supported by Al-Maghrabi who noted that 63%  of tumors with lymph node 
involvement tested positive for COX-2 while only 37% of the cases with no 
COX-2 expression had lymph node involvement 63. 
           In addition to confirming these observations, and furthur evaluating the 
association between COX-2 expression and lymph node involvement, Masunga 
and others found  a significant correlation between increased COX-2 expression 
and presence of more than three metastatic lymph nodes (N2) 62. A similar 
further evaluation revealed more frequent COX-2 expression in metastatic 
lymph nodes compared to the primary tumors 57,63. 
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(iv)Distant metastasis: 
           Among the three studies evaluating the association of COX-2 
overexpression  with distant metastasis, Soumaro LT 57 and Al-Maghrabi 63 in 
their works have found a higher hematogenous metastasis in COX-2 positive 
patients. The former in addition have described  100% COX-2 expression in the 
metastatic sites  compared to a 71% expression in the primary tumor.    
          Tomozawa S and others further classified the COX-2 positive tumors into 
low positive and high positive groups considering both the intensity and extent 
of positive reaction of tumor cells 64. Low positive groups included grade 1 and 
grade 2 which showed weaker COX-2 expression than mononuclear cells. The 
high positive groups included grade 3 and 4 which showed COX-2 expression 
either similar or stronger than mononuclear cells. The high COX-2 expression 
strongly correlated with hematogenous metastasis. 
          In all the three studies COX-2 overexpression was in addition also 
associated with tumor recurrence. 
(v) Microscopic grade and type: 
          Increased COX-2 expression is significantly correlated with tumor 
differentiation. Poorly differentiated carcinomas more frequently expressed 
COX-2 compared to the well and moderately differentiated carcinoma 62,63 . 
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However no such statistically significant association was observed by Soumaro 
LT and Tomozawa S in their studies. 
          Evaluating the COX-2 expression in carcinoma with signet ring cell and 
mucinous component, Ogino S and others observed that the mucinous group 
showed higher levels of  COX-2 along with KRAS mutations than the signet 
ring group which showed lower COX-2 level 65. However an elevated COX-2 
expression was noted both in the mucinous and signet ring cell colorectal 
carcinoma by Baba and others who found in addition, PTGER2 overexpression 
to be associated with microsatellite instability 66 . 
(vi) Tumor size :  
         Fujita T and others have demonstrated high COX-2 mRNA levels in larger 
tumors. The tumors were divided into three classes: ≤ 3 cm, ≤ 6 cm and > 6 cms 
and the tumor surface areas were calculated. The COX-2 mRNA levels were 
then determined by PCR method 59.  
          Other studies also showed greater COX-2 expression in larger tumors, 
where COX-2 expression was determined by immunohistochemistry 57,61,62 . A 
maximum tumor diameter of  > 3 cms was regarded as an unfavourable findings 
by Masunaga R and others 62 . No such association was seen in other studies by 
Tomozawa S 64 . 
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(vii) Tumor location :   
          A more frequent COX-2 expression in left colonic carcinoma (67%) 
compared to right colonic carcinoma (33%) has been reported by Nasir A and 
others 67 . The authors give a possible explanation  for the same relating it to the 
genetic alterations – APC mutations seen frequently in the left sided carcinoma. 
In addition, reduced COX-2 expression has been documented in DNA mismatch 
repair gene defective tumors 68,69 .  
          However no such association between location of tumor and COX-2 
expression has been reported by others 57,63. 
(viii) Vascular, lymphatic and neural invasion :   
          More frequent vascular and lymphatic invasion has been reported in 
tumors with COX-2 overexpression by Soumaro LT 57. However no such 
significant association was seen by Sheehan and others who evaluated the 
relation between neural invasion in addition to vascular and lymphatic invasion 
with COX-2 expression 61 . 
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COX-2 : A TARGET FOR CANCER CHEMOTHERAPY 
          It can be inferred from literature review that colorectal carcinoma with 
higher COX-2 gene expression grow larger and in a more invasive manner. 
Further a significant correlation between high COX-2 expression and a 
shortened patient survival has been documented 57,61,63 . Sheehan KM and others 
found a 5 years survival rate of  91.6% in the absence of COX-2 compared to 
40.5%  in tumors expressing COX-2 61.  
          Taking into consideration both the stage of the tumor and COX-2 
expression,  Soumaro LT and others have reported a five year survival rate of  
COX-2 negative and COX-2 positive cases in stage I and II as 97% and 82% 
respectively and that in stage III as 88% and 67% 57 . Analysing the morbidity 
of the patients, a major difference was seen in the disease free survival between 
patients with COX-2 positive and negative tumors 63. A recurrence of 85% was 
seen in patients with COX-2 expressing tumors compared to 40% in patients 
with COX-2 negative tumors. 
          Colorectal tumors with COX-2 overexpression are at high risk for local, 
distant recurrence and because of the strong adverse impact on survival, these 
patients are appropriate candidates for COX-2 inhibitor therapy. 
          Epidemiological studies show that the regular use of aspirin and other 
NSAIDS reduces the risk of colorectal carcinoma by 40-50%. Further a 
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regression of preexisting adenomas in patients with FAP (Familial 
Adenomatous  Polyposis)  has been documented 70 .  
          However the use of aspirin is limited by its adverse effects on the gastric 
mucosa since both the activity of COX-1 and COX-2 are blocked thereby 
decreasing the levels of cytoprotective prostaglandins formed by COX-1 
activity. This necessitates the need for a COX-2 selective inhibitor. 
          Selective COX-2 inhibitors include- Celecoxib, Rofecoxib, L-745,337, 
SC 58125, Etodolac and Meloxicam . The newer drugs L-745,337 and SC 
58125 have 100 fold selectivity for COX-271. Another COX-2 selective 
inhibitor NS-398 has been found to induce apoptosis by elevating caspase-3 
activity. 
          Celecoxib inhibited the incidence and multiplicity of colon tumors by    
93 % and 97%. Rofecoxib enhances the effects of antineoplastic agents like     
5-Flurouracil 70 .  The drug decrease the expression of COX-2 along with cyclin 
D1, cytosolic  β catenin, MMP-2 and MMP-9, VEGF as seen by animal studies . 
          In addition to chemotherapy, prognosis after radiotherapy is also 
associated with COX-2 levels as determined by Heer PD and others . The 
authors observed that  tumors with high COX-2 expression after radiotherapy 
showed higher rate of distant recurrences, poor disease-free survival and poor 
overall survival 69 . This is because COX-2 is known to induce bcl-2 and cause 
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apoptosis resistance as already discussed. Addition of COX-2 inhibitors to 
preoperative radiotherapy therefore may help to reduce metastasis and improve 
survival. Celecoxib has been evaluated for use in combination with 
chemotherapy for treating patients with metastatic disease who failed prior 
chemotherapy. 
 
COX-2 AND OTHER CARCINOMA : 
          COX-2 overexpression is not confined to only colorectal carcinoma. An 
overexpression  has been seen in lung 72 , breast 73 , prostate 74 ,esophagus 75 and 
endothelium 47.  COX-2 overexpression has been seen in the non-small cell lung 
cancers- adenocarcinomas and squamous cell carcinomas 72 . 
          In patients with prostatic carcinoma with metastasis, a strong COX-2 
expression along with Ki-67 expression was noted in the epithelial cells 
compared to the non-metastatic prostatic cancer group 74 . Further high intensity 
of COX-2 staining tumor cells was strongly associated with prostate cancer 
related death.  
          Marked COX-2 expression has been documented in squamous cell 
carcinoma and  squamous dysplasia with no expression in normal epithelium in 
the esophagus by  RT-PCR 75 .   
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          Analysing the effect of COX-2 overexpression in endometrial carcinoma, 
Ohnos and others found that its overexpression was associated with advanced 
FIGO stage and invasion into outer half of the myometrium 76. However grade 
of differentiation, menopausal status and lymph node metastasis had no 
association with COX-2 overexpression. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Materials and Methods 
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MATERIAL AND METHODS : 
          65 consecutive cases of colorectal carcinoma between January 2009 to 
December 2013 were retrieved from the records of the pathology department at 
PSG IMS&R. The paraffin- embedded H & E slides of the 65 cases were 
examined. The location, histological type and grade of the neoplasm, depth of 
invasion, lymph node metastasis were observed. Clinical details which included 
the age, sex, stage of tumor were recorded. The representative slides were 
selected in each case which included – primary tumor, lymph node, satellite 
nodule ( if any ), distant metastatic deposits ( if any ). The cases which was 
diagnosed as medullary carcinoma, neuroendocrine carcinoma, squamous 
carcinoma, adenosquamous carcinoma and choriocarcinoma were excluded.  
Immunohistochemical staining for COX-2 was done by the following  
procedure 77. 
          Section were cut at approximately 4 micrometer, floated on to Poly-L-
Lysine coated slides and incubated at 37 degree Celsius for one day and further 
incubated at 58 degree Celsius over night. Deparaffinization was done in 2 
changes of  Xylene each for 15 min followed by dexylinization in 2 changes of 
absolute alcohol. Dealcoholisation  was  done by graded alcohol 90% and 70 % 
alcohol each for 1 min. Rehydration was done in tap water for 10 min and 
rinsed in distilled water for 5 min. 
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          Antigen retrieval was done by pressure cooking in citrate buffer ( pH -
6.0) for 10 min and leaving  the pressure cooker in the sink with water for 20 
min . The slides were then rinsed in distilled water for 5 min . The slides were 
transferred to TBS ( Tris-Buffer Solution ) ( pH 7.6) for 5 min. 
          Peroxidise block was done for 10 to 15 min. The slides were then washed 
in TBS buffer 3 times each lasting for 5 min. To block non specific reaction 
with the other tissue antigen, power block was done for 15 min. The slides were 
drained and the sections were covered with concerned primary antibody to 
detect the tumor markers by antigen antibody reaction for 1 hr. The slides were 
then washed in TBS 3 times, each for 5 min to wash the unbound antibodies.To 
enhance the reaction between primary and secondary antibodies, super enhancer 
was added and left for 30 min. It was washed with TBS buffer 3 times, each for 
5 min to remove the unbound antibodies. To elongate chain and also to label the 
enzyme, Super sensitive Poly- HRP was added. This was followed by washing 
in TBS buffer to remove the unbound antibodies. To give colour to the antigens, 
the slides were treated with colour development solution for 5-8 min. It was  
followed by wash in TBS buffer and the tap water each for 5 min. 
Counterstaining with haematoxylin stain for 1 min was done and  the excess 
stain was washed  in tap water for 5 min. The slide is air dried, cleared in xylene 
and mounted with DPX.  
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          A section of lung adenocarcinoma  was used as positive control and the 
negative control was the same tissue incubated without secondary          
antibody70.The Antibody solutions used were THERMO Scientific- Monoclonal 
Rabbit Anti-Human COX-2 clone  . The chromogen in the colour development 
solution was 3’3’ diaminobenzidine (DAB). 
COX-2 cytoplasmic staining was evaluated using a method which takes into 
consideration both the proportion of positive cells and the intensity of     
staining 57,64 . The method is as follows: 
EXTENT OF STAINING 
(proportion score PS) 
PERCENTAGE OF POSITIVE CELLS 
0 
1 
2 
3 
4 
0% 
1% - 25% 
26% - 50% 
51% - 75% 
76% - 100% 
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INTENSITY SCORE ( IS ) INTENSITY OF POSITIVITY 
0 
1 
2 
3 
Negative 
Weak * 
Intermediate ** 
Strong *** 
*Weaker than inflammatory cells 
**Same as inflammatory cells 
***Stronger than inflammatory cells 
The extent of staining and the intensity of staining were added together for a 
total score. 
Total score ( PS + IS ) Interpretation 
0 , 2 
3 , 4 , 
5 , 6 , 7 
Negative 
Low positive 
High positive 
 
 
 
 
 
  
 
 
 
 
 
 
Results 
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RESULTS : 
          Of the 65 cases of colorectal carcinomas included in the study, 56             
(86.2% ) cases expressed COX-2 while 9 cases ( 13.8% ) were COX-2 negative. 
Twelve of the 56 positive cases ( 21.4% ) ( 12/65 = 28.5% ) had a total COX-2 
score of either 3 or 4 and were classified as low positive. The remaining 44 
cases ( 78.6% ) ( 44/65 = 67.7% ) were high positive with a COX-2 score 
between 5 and 7 as shown in Table 1. 
Table 1 : Shows the distribution of COX-2 expression in colorectal carcinoma : 
 
TOTAL NO. OF 
CASES 
COX-2 EXPRESSION 
NEGATIVE POSITIVE 
LOW POSITIVE HIGH POSITIVE 
65 9 (13.8% ) 12 ( 28.5% ) 44 ( 67.7 % ) 
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COX-2 NEGATIVE CASES : 
          4 of the 9 COX-2 negative cases did not show any expression of COX-2. 
Less than 25% of  tumor cells of 5 other cases however weakly expressed  
COX-2 accounting to a total score of  2 which was considered negative. The 
details of the 9 COX-2 negative cases have been shown in table-2. 
          No lymph node metastasis was seen in 7 of the nine (77.8% ) COX-2 
negative cases. Only 2 cases (22.2% ) had tumor in the lymph node and the 
tumor cells in one of them were low positive for COX-2. 
           7 cases (77.8% ) and 2 cases (22.2% ) were in stage II and stage III 
respectively. There were no stage I and stage IV tumors. 3 cases ( 33.3% ) were 
well-differentiated while 6 ( 66.7% ) were moderately-differentiated carcinoma. 
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Table 2 : Shows Stage, Microscopic grade, COX-2 score  and Location of 
COX-2 negative Carcinoma: 
Sl.no STAGE OF  
TUMOR 
MICROSCOPIC 
GRADE OF 
ADENOCARCINOMA 
COX-2  
SCORE 
LOCATION 
OF TUMOR 
1 II A    T3N0M0 Well-differentiated 0 Left 
2 II B     T4N0M0 Moderately differentiated 0 Left 
3 II A    T3N0M0 Moderately differentiated 2 Right 
4 IIIB    T3N1M0 Moderately differentiated 2 Left 
5 IIB     T4N0M0 Moderately differentiated 2 Right 
6 IIB     T4N0M0 Moderately differentiated 0 Right 
7 IIA    T3N0M0 Moderately differentiated 0 Right 
8 IIA    T3N0M0 Well differentiated 2 Right 
9 III      T1N1M0 Well differentiated 2 Left 
 
          T1, T3 and T4 tumors constituted 11.1% ( 1 case), 55.6% ( 5 cases ) and 
33.3% ( 3 cases). However the satellite nodules of the T4 tumors expressed 
COX-2 ( low positive ). 
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COX-2 LOW POSITIVE CASES : 
          The stage and the degree of differentiation of the 12 low positive cases     
( 12 of 65, 18.5% ) has been shown in Table- 3. 
           Nine cases (75%) had no evidence of tumor in the lymph node. Of the 3 
cases (25%) with lymph node deposits, a similar COX-2 expression was seen in 
both the primary tumor and the lymph node deposits in 2 cases while a higher 
expression was seen in the lymph node deposits in the third case in the N2 
stage. 
       Two stage I tumors (16.7% ), seven stage II tumors (58.3% ) and three 
stage III tumors showed low positivity. Histological examination revealed 4 
(33.3%) well differentiated, 8 (66.7% ) moderately differentiated, 2 (16.7% ) T2 
and 10 (83.3% ) T3 carcinoma. No T4 or T1 carcinoma was seen in this 
category. 
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TABLE-3 : Shows  Location , Stage, Microscopic grade, COX-2 score  of  
COX-2 Low positive carcinoma : 
Sl.no LOCATION 
OF 
TUMOR 
STAGE OF  
TUMOR 
MICROSCOPIC 
GRADE OF 
ADENOCARCINOMA 
COX-2 
SCORE 
1 Left II       T3N0M0 Well differentiated 4 
2 Right IIIB   T3N1M0 Well differentiated 4 
3 Left IIA    T3N0M0 Moderately differentiated 4 
4 Left IIIB    T3N1M0 Moderately differentiated 4 
5 Left IIA     T3N0M0 Moderately differentiated 3 
6 Left IIA    T3N0M0 Moderately differentiated 3 
7 Left IIA    T3N0M0 Moderately differentiated 3 
8 Left IIA    T3N0M0 Moderately differentiated 3 
9 Left IIA    T3N0M0 Moderately differentiated 4 
10 Right IIIC   T3N2M0 Moderately differentiated 4 
11 Right I        T2N0M0 Well differentiated 4 
12 Left I        T2N0M0 Well differentiated 4 
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COX-2 HIGH POSITIVE CASES : 
          The stage and degree of differentiation of  the  44 (44/65 = 67.7% )  
tumors expressing high COX-2 has been shown in Table-4. Lymph node 
deposits was seen in 21 cases (47.7% ) of which 11 were in N1 stage and 10 
were in N2 stage.  In all these cases both the primary tumor and lymph node 
deposit showed a high intensity of COX-2 expression except in 2 cases where 
the primary tumor showed a high positive COX-2 expression, but the lymph 
node showed a lower COX-2 expression. 23 cases (52.3%) did not have lymph 
node metastasis. 
         One (2.2%) T2 tumor, 34 (77.3%) T3 tumors and 9 (20.5%) T4 tumors 
were present in this group. There was no T1 tumor. Stage I, stage II, stage III 
and stage IV tumor constituted 1 case (2.2%), 20 cases (45.5%), 20 cases 
(45.5%) and 3 cases (6.8%) respectively. The organs involved by  distant 
metastasis in the three stage IV tumors were fallopian tube and ovary in two of 
them and an umbilical nodule in the third. One of the former tumors had in 
addition spread to the uterus. Nine cases (20.6%), 28 cases (63.6%) and 5 cases 
(11.4%) were well differentiated, moderately differentiated and mucin secreting 
adenocarcinoma. In addition, there were 1 case each (2.2%) of poorly 
differentiated and signet ring cell carcinoma. 
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TABLE -4 : Showing Location, Stage, Microscopic grade and COX-2 score in 
COX-2 high positive carcinoma : 
Sl.no LOCATION 
OF TUMOR 
STAGE OF 
TUMOR 
MICROSCOPIC GRADE 
AND TYPE OF 
ADENOCARCINOMA 
COX-2 
SCORE 
1 Left IIA  T3N0M0 Moderately differntiated 7 
2 Left IIIC  T3N2M0 Moderately differentiated 7 
3 Right IIA  T3N0M0 Moderately differentiated 6 
4 Left IIA   T3N0M0 Moderately differentiated 5 
5 Right IIIB  T3N1M0 Mucinous adenocarcinoma 6 
6 Left IIA   T3N0M0 Moderately differentiated 5 
7 Right IIA    T3N0M0 Mucinous adenocarcinoma 6 
8 Right IIIB   T4N1M0 Poorly differentiated 7 
9 Transverse I         T2N0M0 Mucinous adenocarcinoma 7 
10 Left IIIC   T3N2M0 Well differentiated 6 
11 Left IIIB   T3N1M0 Well differentiated 6 
12 Left IIA    T3N0M0 Well differentiated 6 
13 Right IIIB   T3N1M0 Moderately differentiated 7 
14 Left IIB    T4N0M0 Moderately differentiated 5 
15 Left IIA    T3N0M0 Moderately differentiated 7 
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Sl.no LOCATION 
OF TUMOR 
STAGE OF 
TUMOR 
MICROSCOPIC GRADE 
AND TYPE OF 
ADENOCARCINOMA 
COX-2 
SCORE 
16 Transverse IIA   T3N0M0 Moderately differentiated 6 
17 Left IIIC   T4N2M0 Mucinous adenocarcinoma 6 
18 Right IIIB   T3N1M0 Signet ring cell carcinoma 7 
19 Left IIIB   T4N1M0 Moderately differentiated 7 
20 Left IIA    T3N0M0 Moderately differentiated 5 
21 Right IIB     T4N0M0 Well differentiated 7 
22 Left IIA    T3N0M0 Well differentiated 7 
23 Tranverse IIA  T3N0M0 Well differentiated 5 
24 Left IIIB T3N1M0 Moderately differentiated 7 
25 Left IIIC  T3N2M0 Moderately differentiated 6 
26 Left IV    T4N0M1 Moderately differentiated 6 
27 Left IIIB  T4N1M0 Moderately differentiated 6 
28 Left IIIC   T3N2M0 Moderately differentiated 5 
29 Left IV      T4N0M1 Moderately differentiated 6 
30 Right IIA    T3N0M0 Moderately differentiated 6 
31 Right IIA    T3N0M0 Moderately differentiated 6 
32 Left IIIC   T3N2M0 Moderately differentiated 5 
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33 Right IV     T3N2M1 Moderately differentiated 7 
34 Left IIIB   T3N1M0 Moderately differentiated 6 
35 Left IIA    T3N0M0 Moderately differentiated 5 
36 Right IIA    T3N0M0 Well differentiated 5 
37 Left IIIC   T3N2M0 Moderately differentiated 7 
38 Left IIIC   T3N2M0 Well differentiated 5 
39 Right IIIB   T4N1M0 Mucinous adenocarcinoma 7 
40 Left IIIB   T3N1M0 Well differentiated 6 
41 Left IIA    T3N0M0 Moderately differentiated 7 
42 Left IIIC  T3N2M0 Moderately differentiated 5 
43 Right IIA    T3N0M0 Moderately differentiated 6 
44 Right IIA  T3N0M0 Moderately differentiated 6 
 
COX-2  EXPRESSION AND STAGE OF TUMOR : 
          There were 3 ( 4.6%), 34 (52.3%), 25 (38.5%) and 3(4.6%) tumors of 
stage I, II, III and IV respectively. The pattern of COX-2 expression has been 
shown in Table-5. Of the three stage I tumors, 2 ( 66.7%)  were COX-2 low 
positive and 1 (33.3%) was COX-2 high positive. None of stage I tumors were 
COX-2 negative. Seven ( 20.6%) COX-2 low positive, 20 ( 58.8%) COX-2 high 
positive and 7(20.6%) COX-2 negative tumors constituted the thirty four stage 
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II tumors. The 25 stage III tumors included 3 (12%), 20 (80%) and 2 (8%) 
COX-2 low positive,  high positive and COX-2 negative cases respectively. 
TABLE-5: Showing relation between COX-2 status and the Stages of colorectal 
Carcinoma : 
STAGE OF 
TUMOR 
COX-2 EXPRESSION 
NEGATIVE POSITIVE 
LOW POSITIVE HIGH POSITIVE 
Stage I ( n=3 ) Nil (0%) 2 (66.7%) 1 (33.3%) 
Stage II ( n= 34 ) 7 ( 20.6%) 7 ( 20.6%) 20 ( 58.8%) 
Stage III ( n = 25) 2 (8%) 3 (12%) 20 (80%) 
Stage IV  ( n= 3 ) Nil (0%) Nil (0%) 3 ( 100%) 
 
          All the 3 stage IV tumors (100%) expressed strong COX-2 staining in 
over 70% of their tumor cells; all three were considered high positive. In 
addition, the primary tumor and the distant metastasis exhibited high COX-2 
score in all the three cases. The lymph node deposits and a satellite nodule seen 
in two of these cases also had a COX-2 score of 7 (Table-6). 
 
 
89 
 
TABLE-6 : Shows COX-2 staining in stage IV carcinoma: 
Sl. 
no 
STAGE 
OF 
TUMOR 
ORGAN OF 
METASTASIS 
INTENSITY OF COX-2 STAINING 
( COX-2   SCORE) 
PRIMARY 
TUMOR 
LYMPH 
NODE 
SATELLITE 
NODULE 
METASTATIC 
SITE 
1 T4N0M1 Fallopian tube 
& ovary 
6 - 7 7 
7 
2 T4N0M1 Uterus, 
fallopian tube 
& ovary 
6 - 6 5 
6 
5 
3 T4N2M1 Umbilical 
nodule 
7 7 7 7 
 
 
 
COX-2 AND DEPTH OF INVASION : 
Of the 65 cases of colorectal carcinoma, 1(1.5%), 3(4.6%), 48 ( 73.9%) and 13 
(20%) were T1,T2, T3 and T4 tumors respectively. The intensity of COX-2 
staining in these tumors have been shown in table-7. 
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TABLE-7 : Shows relation between COX-2 expression and depth of invasion 
of  Colorectal carcinoma : 
DEPTH OF 
INVASION 
COX-2 EXPRESSION 
NEGATIVE POSITIVE 
LOW POSITIVE HIGH POSITIVE 
T1 (n=1) 1 (100%) Nil  (0%) Nil (0%) 
T2 (n=3) Nil 2 ( 66.7%) 1 (33.3%) 
T3(n=48) 5 ( 10.4%) 10 (20.8%) 33 (68.8%) 
T4 (n=13) 3 (23%) Nil (0%) 10 (77%) 
            
 
The   single T1 tumor was COX-2 negative (100%). Of  the 3 tumors in T2 
stage, 2 (66.7%) were low positive while the other was high positive. Five 
COX-2 negative (10.4%), 10 low positive (20.8%) and 33 high positive( 68.8%) 
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cases consitituted  the 48 T3 tumors. The thirteen T4 tumors included 3 cox-2 
negative (23%) and ten (77%) high positive tumors. None of T4 tumors were 
low positive for COX-2. 
          In addition, of the five COX-2 negative T3 tumors, three were Rt colonic 
carcinoma and 2 were from the Lt colon. Similarly the three COX-2 negative T4 
tumors included 2 from the Rt colon and one from the Lt colon. 
 
COX-2 EXPRESSION AND HISTOPATHOLOGICAL GRADE, TYPE: 
          The 65 cases of colorectal carcinomas were comprised of  16 cases 
(24.6%), 42 cases (64.7%) and 5 cases (7.7%) of well-differentiated, moderately 
differentiated and mucinous adenocarcinoma respectively. One case each 
(1.5%) of poorly differentiated and signet ring cell adenocarcinoma were 
present in the study.  The pattern of COX-2 expression in these categories have 
been shown in Table-8. 
 
Well-differentiated adenocarcinoma : 
          Of the sixteen well –differentiated adenocarcinomas, 3 (18.8%) COX-2 
negative, 4 (25%) COX-2 low positive and 9( 56.2%) COX-2 high positive 
were present ( Table-8). Lymph node metastasis was seen in one of the four low 
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positive tumors and the tumor deposits in the lymph node were also COX-2 low 
positive. Of the nine high positive cases four had evidence of tumor in the 
lymph node which was also high positive. Both the primary tumor and lymph 
node showed 80% of  tumor cells with moderate to strong COX-2 staining. One 
of the three COX-2 negative tumors had lymph node metastasis. In this case, 
about 10% of cells of the primary tumor exhibited a weak COX-2 expression 
giving a total score of 2 and was regarded as negative, while the tumor cells 
within the lymph nodes were low positive with a total score of 4. 
TABLE-8 : Shows COX-2 expression in the different histological types and 
Grade of colorectal carcinoma : 
HISTOLOGICAL GRADE 
AND TYPE 
COX-2 EXPRESSION 
NEGATIVE LOW 
POSITIVE 
HIGH 
POSITIVE 
Well differentiated 
adenocarcinoma (n=16) 
3 ( 18.8%) 4 ( 25%) 9 (56.2%) 
Moderately differentiated 
adenocarcinoma (n=42) 
6 (14.3%) 8(19%) 28 ( 66.6%) 
Poorly differentiated 
adenocarcinoma (n=1) 
0 0 1(100%) 
Mucinous adenocarcinoma 
(n=5) 
0 0 5 (100%) 
Signet ring cell 
adenocarcinoma (n=1) 
0 0 1 (100%) 
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Moderately differentiated adenocarcinoma : 
         6 cases (14.3%) of COX-2 negative, 8 (19%) cases of low positive and 28 
(66.6%) cases of high positive moderately differentiated adenocarcinoma were 
observed in the present study ( Table-8). 
           One of the six COX-2 negative cases showed lymph node metastasis 
which was also COX-2 negative. Evidence of tumor in the lymph node was seen 
in two of the six low-positive cases. One of these had tumor in more than three 
lymph nodes (N2 stage) and a high COX-2 score was seen in the lymph nodes, 
while the primary tumor was low positive. The lymph node deposits in the other 
low positive tumor had   a similar low COX-2 score as the primary tumor.  
           Of the twenty eight high COX-2 expressing moderately differentiated 
adenocarcinomas, twelve had tumor deposits in the lymph node with seven in 
N2 stage. In five of these tumors in N2 stage, a high COX-2 expression was 
seen both in the primary tumor and lymph node, while in two of them the 
primary tumor had a high COX-2 expression compared to lymph node deposits 
which were low COX-2 positive. A high COX-2 expression was seen both in 
the primary tumor and lymph node deposits in four of the five cases in N1 stage. 
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Poorly-differentiated adenocarcinoma :   
          The single case (1.5%) was COX-2 high positive, stage III (T4N1M0)  
tumor with total COX-2 score of 7 in the primary tumor, lymph node and 
satellite nodule. 
Mucin secreting adenocarcinoma :   
           All the 5 cases expressed a high COX-2 score. Three of these tumors 
belonged to stage III and the other two were in stage I and stage II. The lymph 
node deposits in three stage III tumors and the satellite nodule in the two T4 
tumors also were COX-2 high positive. These features have been summarised in 
table 9. 
Signet ring cell adenocarcinoma : 
The single case of signet ring cell adenocarcinoma present in the study was a 
stage IIIB tumor (T3N1M0) with a high COX-2 expression in the primary 
tumor and omental nodule and a low COX-2 score of 3 in the lymph node. 
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TABLE-9 : Shows Location, Stage and COX-2 expression in mucinous 
adenocarcinoma : 
Sl.no LOCATION STAGE COX-2 SCORE 
PRIMARY 
TUMOR 
LYMPH 
NODE 
SATELLITE 
NODULE 
1 Right IIIB    
T3N1M0 
6 7 No nodule 
2 Right IIA     
T3N0M0 
6 No lymph 
node 
No nodule 
3 Transverse I         
T2N0M0 
7 No lymph 
node 
No nodule 
4 Left III      
T4N2M0 
6 7 7 
5 Right IIIB    
T4N1M0 
7 7 7 
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          Thus 81.25% of well differentiated adenocarcinoma expressed COX-2 
while 85.7% of moderately differentiated carcinoma expressed in COX-2. All 
the cases (100%) of poorly differentiated, mucinous and signet ring cell 
adenocarcinoma expressed COX-2 (Table-8). 
          The relation of COX-2 expression with tumor stage, depth of invasion, 
microscopic type, grade and lymph node metastasis are summarised in Table 
10. 
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COX 2 
EXPRESSION 
AJCC (TNM 
STAGING) 
DEPTH OF 
INVASION 
MICROSCOPIC GRADE LYMPH NODE STATUS 
   I           II  III IV 
      
T1 T2 T3 T4 
WELL  
DIFFERENTIATED  
MOD 
DIFFERENTIATED 
POORLY 
DIFFERENTIATED 
MUCINOUS 
CARCINOMA 
SIGNET RING 
CARCINOMA 
  No 
METASTASIS METASTASIS 
  3 34 25 3 1 3 48 13 16) (42) (1)  (5) (1) (39) 26 
NEG(9) 0 7 2 0 1 0 5 3 3 6 0 0 0 7 2 
                                
LP (12) 2 7 3 0 0 2 10 0 4 8 0 0 0 9 3 
                                
HP (44) 1 20 20 3 0 1 33 10 9 28 1 5 1 23 21 
                                
                                
                                
Table 10:Shows COX-2 expression in various TNM stages, depth of invasion, microscopic grade 
 and lymphnode metastasis. 
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COX-2 EXPRESSION AND LOCATION OF TUMOR : 
          Twenty two cases (33.9%) of  Rt colon carcinoma, 40 cases (61.5%) of  
Lt colon carcinoma and 3 cases (4.6%) of transverse colon carcinoma 
constituted the 65 cases. The   varying COX-2 expression has been shown in 
table 11 
TABLE-11 : Shows cox-2 expression and tumor location : 
LOCATION OF 
TUMOR 
COX-2 NEGATIVE COX-2 POSITIVE 
Right colon (n=22) 5 (22.7%) 17 (77.3%) 
Left colon (n= 40) 4 (10%) 36 (90%) 
Transverse ( n=3) Nil 3 (100%) 
 
          Of the 22 Rt colonic carcinoma, 17 (77.3%) expressed COX-2 and           
5 ( 22.7%) were negative. The forty cases of Lt colonic carcinoma included 4 
(10%)    COX-2 negative tumors and 36 (90%) COX-2 positive tumors. 
COX-2 EXPRESSION AND SIZE OF TUMOR : 
The greatest diameter of the nine COX-2 negative tumors varied between 2.5cm 
and 6.0 cms  ( average 4.6 cms) while those of 65 COX-2 positive  tumors 
ranged from 2.5cms to 12.0 cms ( average 5.3 cms). 
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COMPARISON OF INTENSITY OF COX-2 STAINING BETWEEN 
PRIMARY TUMOR AND LYMPH NODE DEPOSITS IN STAGE III 
TUMORS : 
        Of the twenty five cases of stage III tumors, a similar COX-2 expression 
was seen both in the primary tumor and lymph node deposits in 19 cases (76%). 
In four cases (16%)  a high COX-2 expression was seen in primary tumor while 
the lymph node deposits showed a low COX-2 score, however they were 
positive(shown by astrix in table 12). In one case (4%), both the primary tumor 
and lymph node deposit were negative and in one case (4%) the primary tumor 
was low COX-2 positive while the lymph node was high positive. These 
findings have been shown in table -12. 
TABLE-12 : Shows COX-2 score in primary tumor and lymph node metastasis 
in stage III tumors 
Sl.no TNM STAGE COX-2 EXPRESSION 
PRIMARY TUMOR LYMPH NODE 
1 T3N2M0 7 7 
2 T3N1M0 6 7 
3 T4N1M0 7 7 
4 T3N2M0 6 7 
5 T3N1M0 6 6 
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6 T3N1M0 7 7 
7 T3N1M0 7 3 
8 T4N2M0 6 7 
9* T4N1M0 7 3 
10 T4N1M0 7 7 
11 T3N1M0 4 4 
12 T3N1M0 7 6 
13 T3N2M0 6 5 
14 T4N1M0 6 5 
15 T3N2M0 5 6 
16 T1N1M0 2 4 
17* T3N2M0 5 3 
18* T3N1M0 6 2 
19 T3N2M0 7 7 
20 T3N2M0 5 7 
21 T4N1M0 7 7 
22 T3N1M0 6 7 
23* T3N2M0 5 4 
24 T3N2M0 4 4 
25 T3N1M0 2 0 
 
  
 
 
 
 
 
Fig 1 A : POSITIVE CONTROL: shows   COX-2 expression in  pulmonary  
adenocarcinoma, alveolar spaces are seen(red arrow)(100x). B shows  
strong COX-2 expression  in colon carcinoma , with no expression in  
adjacent normal (red arrow) mucosa(100x).     
A 
B 
  
 
 
 
 
 
 
 
 
 
A B 
C D 
Fig 2 A : shows well differentiated adenocarcinoma (H&E, 100x). B  shows 
strong COX-2 staining in more than 90% of tumor cells with COX2 score of 
(4+3)7 (40x). C shows tumor cells staining stronger than the inflammatory 
cells (400x). D shows  strong C0X-2 expression in satellite nodule in 
mesocolon  similar to  tumor( 40x). 
 
   
 
 
 
 
 
 
 
 
 
 
 
A 
B 
A B 
Fig 3 A shows  moderate COX-2 expression of tumor cells  in comparison with 
inflammatory cells (red arrow)(100x).   B shows  similar findings (400x) 
Fig 4 A shows weak COX-2   expression  in  tumor cells (red arrow)(100x). B 
shows  weak COX-2 cytoplasmic   staining  compared to the internal positive 
control – inflammatory cells (400x) 
  
 
 
 
 
 
 
 
 
 
 
 
A B 
C 
D 
Fig 5 shows   mucinous carcinoma infiltrating the submucosa with abundant 
extracellular mucin(H&E, 40x) .B shows tumor cells floating in pools of 
mucin (H&E,100x).C shows  strong COX-2 expression in the same 
tumor(400x). D shows  strong COX-2 staining in 30% of  metastatic tumor 
cells in the lymph node amidst pools of extracellular mucin .Capsule with 
few lymphoid cells (red arrow)are seen( 100x) 
  
  
 
 
 
 
 
 
  
 
              
       
 
 
 
A 
A 
B 
Fig 6 A shows  signet ring cells (red arrow) infiltrating the muscle 
layer (H&E,100x).B shows strong COX-2 expression in  signet ring 
cells(100x). 
  
 
 
 
 
 
 
 
 
 
                       
 
 
 
 
 
Fig 6 C shows  COX-2 positive metastatic signet ring cells in 
lymph node (100x). D shows   peritoneal nodule with tumor cells 
strongly expressing COX-2 (100X).  
D 
C 
  
 
 
 
 
 
 
Discussion 
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DISCUSSION : 
          Colorectal cancer is the fourth most common cancer in the world and the 
second most common cause of cancer related death 1. Assessment of molecular 
prognostic factors would be of great help for identifying patients who would 
benefit from adjuvant therapies, thereby increasing their survival. 
          Cyclooxygenase-2 (COX-2) and its product PGE2 play an important role 
at multiple levels in colorectal carcinogenesis. It has been implicated from the 
intiation stage to tumor progression 47. The present study was thus done to 
analyse the relation between COX-2 expression and the biological 
characteristics of colorectal carcinoma. In addition to classifying the colorectal 
carcinomas into a positive and a negative group, the COX-2 positive group was 
further divided into COX-2 low positive group which comprised of tumors with 
COX-2 score of 3 an 4 and COX-2 high positive group which included tumors 
with COX-2 score between 5 and 7 64. 
          In the present study of the 65 cases, 86.2% of colorectal carcinomas 
expressed COX-2 while 13.8% did not express. Similar expression has been 
seen  by  Al- Maghrabi who found 85% of colorectal carcinoma expressing 
COX-2 63. However other studies have shown a relatively fewer tumors (70%) 
expressing COX-2 57. This difference could be attributed to the location of the 
tumor. In the former, similar to our study greater numbers of left colon 
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carcinoma were present, while in the latter a greater number of right colon 
carcinoma were included. Right colon carcinoma are more frequently associated 
with microsatellite instability and lower or absent COX-2 expression 67. In 
agreement with these findings, 90% of left colon carcinomas were COX-2 
positive while only 77.3% of right  colon carcinomas expressed COX-2 in the 
present study. 
          Lymph node metastasis was present in 22.2%, 25% and 47.75% of    
COX-2 negative, low positive and high positive cases respectively. These 
findings are in corroboration with those of Sheehan KM 61 and Al-Maghrabi 63 
who also found 2 to 4 times more frequent lymph node metastasis in tumors 
with high COX-2 expression. However the values were not statistically 
significant. Further  as discussed above , 86.2% of primary tumors expressed 
COX-2 while 91.7% of the metastatic lymph nodes were COX-2 positive. A 
similar more frequent COX-2 expression in lymph node compared to the 
primary tumor has been reported by Soumaoro 57 and Al-Maghrabi 63 . 
           Evaluating the proportion of tumor cells expressing COX-2 , Xiong 78 
and others have described strong COX-2 expression in an average of 87% of 
cells of primary tumor in contrast to 100% COX-2 staining in cancer cells of 
lymph node metastatic lesions. Such an observation was seen in the present 
study also. A similar COX-2 score was seen in 76% of stage III tumors in the 
primary tumor and lymph node tumor cells while  in 4% of tumors  few primary 
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tumor cells expressed COX-2 giving a  low COX-2 score while more number of 
tumor cells in the lymph node expressed COX-2 and had a higher score. COX-2 
expression conferring a higher metastatic potential to the tumor cells could 
explain the process. 
          With increasing stage of the tumor, there was an increase in the high 
COX-2 positive tumors from 33.3%, 58.8%, 80% to 100% in stage I, II, III, IV 
respectively. The low COX-2 expressing tumors gradually declined and there 
was no COX-2 negative carcinoma in stage IV. These findings are in correlation 
with other studies which either used the Dukes 61,62 or the AJCC staging  
systems 59,63, but did not reach statistically significant levels. None of the stage I 
tumor were COX-2 negative, but 20.6%  and 8% of stage II and stage III tumors 
were COX-2 negative. This could be explained by the heterogenous population 
of right and left colon carcinomas in stage II and III  as compared to the three 
stage I tumors  which were from right, left and transverse colon. 
          As the tumor progressed from T1 to T4, invading the submucosa, 
muscularis propria, serosa and beyond, an increase in the proportion of high 
COX-2 positive carcinoma from 0% to 77% was observed with a decline in the 
low COX-2 positive tumors from T2 to T3. This association was statistically 
significant p=0.021(p<0.05). A similar relation between depth of invasion and 
COX-2 overexpression has been documented by Soumaoro LT 57and Wu AW 58 
in their studies. In the present study, none of the T2 tumors were COX-2 
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negative, but 10.4% of T3 tumors and 23% of  T4 tumors were negative as right 
colonic carcinomas constituted majority of the tumors of these two groups. 
          High COX-2 expression was seen with lesser degree of differentiation 
which increased from 56.2% to 66.6% and 100% in well differentiated, 
moderately differentiated and poorly differentiated carcinoma. In addition there 
was a decline in the COX-2 negative and COX-2 low-positive carcinomas with 
a shift towards COX-2 overexpression. Our findings are supported by 
Masunaga 62 and Al-Maghrabi J 63. The values were not statistically significant.  
          100% of the mucinous and signet ring cell carcinomas overexpressed 
COX-2 (high COX-2 positive). These findings are in agreement with those by 
Baba Y and others 66. A few others have described a relatively low COX-2 
expression in signet ring cell carcinoma 65 compared to the mucinous category. 
But in the present study a high COX-2 expression was seen in the single case of 
signet ring cell carcinoma. 
          Comparing the COX-2 scores with the tumor size, in the present study no 
correlation was seen between the two as was seen in other studies 57,61 .Tumors 
with maximum diameter of 2.5cms strongly expressed COX-2 giving a total 
score of  7 while a few tumors as large as 7 cms in greatest diameter had a low 
COX-2 score of 4. In addition to the size of tumor, other morphological features 
such as degree of differentiation, depth of invasion and stage also determined 
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the COX-2 overexpression. A similar lack of association between tumor size 
and COX-2 overexpression has been reported by Tomozawa S 64. 
          Further comparing the COX-2 scores of the primary tumor and the distant 
metastasis in the three stage IV tumors in the study, a strong intensity of COX-2 
staining was noted both in primary tumor and metastatic site in the uterus, 
fallopian tube, ovary, umbilical nodule giving a total COX-2 score between 5 
and 7-High COX-2 expression. These features further emphasize the role of 
COX-2 in tumor progression. 
          Thus a correlation between COX-2 expression and tumor biological 
characters like depth of invasion ( statistically significant p=0.021), stage of 
tumor, microscopic grade of tumor and lymph node status was seen in the 
present study. No correlation with tumor size was noted.  
 
 
 
 
 
 
  
 
 
 
 
 
 
Summary and Conclusion 
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SUMMARY : 
1 Colorectal carcinoma is the fourth most common cancer in the world, 
with Cyclooxygenase-2 (COX-2) and its product PGE2 playing an 
important role at multiple levels in the pathway of colorectal 
carcinogenesis. 
2 The inducible cyclooxygenase which is COX-2 is expressed 
constitutively only in placenta, macula densa of kidney and brain. 
3 COX-2 is either absent or expressed at very low levels in the normal 
colonic mucosa derived from the neuroendocrine cells, macrophages and 
vascular endothelial cells. 
4 COX-2 is induced by growth factors, cytokines, oncogenes, nuclear factor 
kB, IL-6 (Interleukin-6) all of which upregulate COX-2. 
5 COX-2 is the enzyme that catalyzes the biosynthesis of prostaglandins 
from arachidonic acid. 
6 COX-2 expression favours evasion of apoptosis by increasing bcl-2 
expression and inhibition of  Fas-mediated apoptosis. It also stimulates 
the APC-β catenin pathway, increases the expression of vascular 
endothelial growth factor (VEGF), decreases E-cadherin expression 
favouring epithelial-mesenchymal transition (EMT) and increases matrix 
metalloproteinases-2 (MMP-2) thereby enhancing the invasiveness and 
metastatic potential of the tumor cells. 
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7 The proportion of cells expressing COX-2 and the intensity of staining 
were both considered to calculate total COX-2 score which ranged from   
0 to 7. 
8 Of the 65 cases of colorectal carcinoma, 86.2% (56 cases) expressed 
COX-2 (COX-2 score 3 to 7) and 13.8% (9 cases ) were COX-2 negative 
(COX-2 score < or =2). 
9 12 cases (12/65=18.5%) had a COX-2 score of either 3 or 4 and were 
designated as COX-2 low positive. The remaining 44 cases (44/65= 
67.7%) had a COX-2 score between 5 and 7 and belonged to COX-2 high 
positive group. 
10 COX-2 expression was more frequently observed in left colon carcinoma 
(90%) than  the right colon carcinoma (77.3%). 
11 The presence of lymph node metastasis increased (22.2% to 25% to 
47.7%) with the increasing levels of COX-2 expression (negative to low 
positive to high positive) in primary tumor. 
12 A more frequent COX-2 expression (91.7%) in the metastatic lymph 
nodes was seen compared to the primary tumor (86.2%). 
13 With increasing stage of the tumor from stage I, II, III to IV, there was an 
increase in the high COX-2 positive tumors from 33.3%, 58.8%, 80% to 
100%. 
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14 As the tumor progressed from T1 to T4 invading the submucosa, 
muscularis propria, serosa and beyond, an increase in the proportion of 
tumor cells expressing COX-2 and an increase in the intensity of staining 
were observed thereby leading to an increase in high COX-2 positive 
tumors. These findings were statistically significant p=0.021 (P<0.05). 
15 More frequent high COX-2 positive tumors were encountered with lesser 
degree of differentiation which varied from 56.2% and 66.6% to 100% in 
the well-differentiated, moderately differentiated and poorly 
differentiated carcinoma respectively. 
16  Mucinous carcinoma and signet ring cell carcinomas also expressed high 
COX-2 score. 
17 Thus in the present study COX-2 overexpression was associated with 
increasing lymph node metastasis, depth of invasion, stage of tumor, 
distant metastasis and decreasing degree of differentiation of tumor. No 
association was observed with tumor size. 
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CONCLUSION : 
            COX-2 the inducible  isoform of cyclooxygenase expressed at 
sites of inflammation has recently emerged as a promising target for 
cancer therapy. In contrast to normal tissues in which COX-2 is either 
absent or expressed at very low levels, COX-2 is consitutively expressed 
in a variety of malignant tumors of  colon, rectum, stomach, esophagus, 
pancreas, lung, breast and endometrium. 
 
          COX-2 is not only involved in early stages of colorectal 
carcinogenesis, but its rate of expression increases with the course of 
cancer development as seen in the present study. COX-2 expression 
increased with increasing stage, depth of invasion, lymph node 
involvement and a lesser degree of differentiation. Thus COX-2 acts at 
multiple levels in colorectal carcinogenesis and determines the prognosis, 
disease-free survival rate and the overall survival rate of the patients. 
These findings justify the use of a selective COX-2 inhibitor as an 
adjuvant to chemotherapy and radiotherapy. It gives an added advantage 
of increasing the response to these therapies by decreasing the bcl-2 
levels, otherwise raised by COX-2. 
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          With the advent of selective COX-2 inhibitors which do not cause 
gastric complications, better patient compliance can also be achieved. 
The newer selective COX-2 inhibitors preferred  are  Celecoxib,  
Rofecoxib,  L-745,337 and   SC58125 . 
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Master chart 
S.NO HP NO Age/Sex Tumor
Max Tumor 
diameter
Histopathological         TNM COX 2 SCORE
location in cms grade   STAGING Primary tumor Lymph node Satellite  nodule  Distant metastasis
R/L/T PS +IS=TS LP/HP PS+IS=TS LP/HP PS+IS=TS LP/HP PS+IS=TS LP/HP
1 332/09 70/M L 6.5cm Moderately differentiated T3N0M0       IIA 4+3=7 HP
2 400/09 42/M L 2.5cm Moderately differentiated T3N2M0       IIIC 4+3=7 HP 4+3=7 HP
3 760/09 79/M R 6cm Moderately differentiated T3N0M0       IIA 3+3=6 HP
4 1944/09 75/F L 4cm Moderately differentiated T3N0M0       IIA 4+1=5 HP
5 2386/09 69/F R 6cm Mucin secreting adenoca T3N1M0     IIIB 3+3=6 HP 4+3=7 HP
6 2432/09 72/M L 4.5cm Moderately differentiated T3N0M0       IIA 2+3=5 HP
7 2655/09 52/M R 4.5cm Mucin secreting adenoca T3N0M0       IIA 4+2=6 HP
8 2757/09 45/M R 6cm Poorly diff mucinous T4N1M0      IIIB 4+3=7 HP 4+3=7 HP 4+3=7(mc) HP
9 2843/09 76/M L 3.5cm Well  diff T3N0M0       IIA 0+0=0 Neg
10 3021/09 65/M T 3cm mucinous colloid type T2N0M0        I 4+3=7 HP
11 3196/09 43/M L 5 cm Well differentiated T3N2M0       IIIC 3+3=6 HP 4+3=7 HP
12 3209/09 47/F L 4cm Well differentiated T3N0M0       IIA 1+3=4 LP
13 3891/09 60/F L 6cm Well differentiated T3N1M0     IIIB 4+2=6 HP 4+2=6 HP
14 3912/09 48/M L 4.5cm Well differentiated T3N0M0       IIA 3+3=6 HP
15 4919/09 61/M R 12cm Moderately differentiated T3N1M0     IIIB 4+3=7 HP 4=3=7 HP
16 5011/09 56/F R 2.2cm Well differentiated T2N0M0        I 3+1=4 LP
17 5041/09 38/F L 3.2cm Moderately differentiated T4N0M0       IIB 3+2=5 HP 3+3=6 HP
18 337/10 83/M L 4cm Moderately differentiated T3N0M0       IIA 4+3=7 HP
19 883/10 55/F L 6cm Moderately differentiated T4N0M0       IIB 0+0=0 Neg 1+2=3 LP
20 979/10 74/M T 6cm Moderately differentiated T3N0M0       IIA 4+2=6 HP
21 1792/10 69/M R 6cm Well diff T3N1M0     IIIB 3+1=4 LP 2+1=3 LP
22 1938/10 63/m L 6cm Mucinous adenoca T4N2M0      IIIC 3+3=6 HP 4+3=7 HP 4+3=7 HP
23 1950/10 72/m R 5cm Moderately differentiated T3N0M0       IIA 1+1=2 Neg
24 2373/10 70/M R 3 cm Signet ring cell ca T4N1M0      IIIB 4+3=7 HP 1+2=3 LP 3+3=6            HP HP
25 2658/10 53/F L 5cm Moderately differentiated T3N1M0     IIIB 1+1=2 Neg 0+0=0 Neg
26 3817/10 76/M R 5cm Moderately differentiated T4N0M0       IIB 1+1=2 Neg 1+2=3 LP
27 3912/10 43/F L 2cm Moderately differentiated T3N0M0       IIA 2+2=4 LP
28 4340/10 63/F L 4.5cm Moderately differentiated T4N1M0      IIIB 4+3=7 HP 4+3=7 HP 3+3=6 HP
29 4542/10 71/M R 4cm Moderately differentiated T4N0M0       IIB 0+0=0 Neg 1+2=3             LP LP
30 4609/10 64/F L 5cm Moderately differentiated T3N1M0     IIIB 1+3=4 LP 1+3=4 LP
31 4841/10 40/F L 4cm Moderately differentiated T3N0M0       IIA 4+1=5 HP
32 45/11 78/F R 4cm Well differentiated T4N0M0       IIB 4+3=7 HP 3+3=6   HP
33 646/11 57/F R 5cm Moderately differentiated T3N0M0       IIA 0+0=0 Neg
34 2122/11 69/F L 3cm Well differentiated T3N0M0       IIA 4+3=7 HP
35 2487/11 70/M T 6cm Well differentiated T3N0M0       IIA 2+3=5 HP
36 3022/11 62/M L 5.5cm Moderately differentiated T3N0M0       IIA 2+1=3 LP
37 3233/11 58/F L 3.5 cm Moderately differentiated T3N0M0       IIA 1+2=3 LP
38 3503/11 66/F R 2.5 cm Well differentiated T3N0M0       IIA 1+1=2 Neg
39 3592/11 85/M L 1.5 cm Moderately differentiated T3N1M0     IIIB 4+3=7 HP 3+3=6 HP
40 3676/11 72/M L 6cm well -differentiated T2N0M0        I 3+1=4   LP
41 3703/11 62/F L 5cm Moderately differentiated T3N2M0       IIIC 4+2=6 HP 3+2=5 HP
42 4447/11 76/F L 2.5 cm Moderately differentiated T4N0M1      IV 3+3=6 HP 4+3=7 HP 4+3=7 HP(FT)
ovary 10.5*10*2.5 cm 4+3=7 HP(Ovary)
43 4510/11 71/M L 4cm Moderately differentiated T3N0M0       IIA 1+2=3 LP
44 4591/11 60/F L 4cm Moderately differentiated T4N1M0      IIIB 3+3=6 HP 4+1=5 HP 3+3=6 HP
45 5051/11 77/M L 5cm Moderately differentiated T3N0M0       IIA 1+2=3 LP
46 5091/11 60/M L 6cm Moderately differentiated T3N2M0       IIIC 3+2=5 HP 4+2=6 HP
47 626/12 61/F L 5cm Well differentiated T1N1M0      IIIA 1+1=2 Neg 3+1=4 LP
48 685/12 85/F L 5cm Moderately differentiated T3N0M0       IIA 3+1=4 LP
49 1289/12 69/F L 5cm Moderately differentiated T4N0M1      IV 4+2=6 HP 3+3=6 HP 4+1=5 HP-Uterus
uterus 1.6*1.5*1.2cm 4+2=6 HP-FT
3+2=5 HP-Ovary
50 1675/12 93/M R 8cm Moderately differentiated T3N0M0       IIA 4+2=6 HP
51 2134/12 59/M R 8cm Moderately differentiated T3N0M0       IIA 4+2=6 HP
52 2513/12 46/M L 4cm Moderately differentiated T3N2M0       IIIC 3+2=5 HP 2+1=3 LP
53 2548/12 79/F R 9cm Moderately differentiated T4N2M1        IV 4+3=7 HP 4+3=7 HP 4+3=7 HP 4+3=7 HP
54 3160/12 61/F L 6cm Moderately differentiated T3N1M0     IIIB 3+3=6 HP 1+1=2 Neg
55 3176/12 77/M L 4.5cm Moderately differentiated T3N0M0       IIA 3+2=5 HP
56 3437/12 70/M R 7cm Well differentiated T3N0M0       IIA 2+3=5 HP
57 4532/12 67/F L 6cm Moderately differentiated T3N2M0       IIIC 4+3=7 HP 4+3=7 HP
58 4627/12 55/M L 5.5cm Well differentiated T3N2M0       IIIC 3+2=5 HP 4+3=7 HP
59 4713/12 41/M R 9.5cm  well differentiated mucin T4N1M0      IIIB 4+3=7 HP 4+3=7 HP 4+3=7 HP
60 4959/12 85/F L 5cm Well differentiated T3N1M0     IIIB 3+3=6 HP 4+3=7 HP
61 184/13 56/M L 4.5cm Moderately differentiated T3N0M0       IIA 4+3=7 HP
62 256/13 45/F L 5cm Moderately differentiated T3N2M0       IIIC 2+3=5 HP 3+1=4 LP
63 698/13 56/F R 7cm Moderately differentiated T3N2M0       IIIC 3+1=4 LP 4+1=5 HP
64 1018/13 61/M R 6cm Moderately differentiated T3N0M0       IIA 3+3=6 HP
65 1885/13 79/M R 8cm Moderately differentiated T3N0M0       IIA 3+3=6 HP
